The quest for immortality has become serious business
原文媒体
The Economist(《经济学人》)|商业与生物技术
原文发布时间
2026年11月3日
核心议题
长寿商业化|健康寿命|医学证据|GLP-1|生物年龄|抗衰老研发
适合读者
英语四级进阶/六级/考研/雅思/托福;对健康科技感兴趣的普通读者
01|开头导语
当“活得更久”成为可以付费购买的体验:一次极低温舱、一次全身磁共振、几瓶补充剂,真能让人延长寿命吗?
《经济学人》把伦敦一家长寿诊所的套餐、科技富豪投资和实验性抗衰老药物放在同一篇报道里。
读这篇文章,最值得思考的是:哪些是医学事实,哪些只是吸引消费者的未来想象?
图1|原文配图:冰块中的玫瑰,暗示“留住青春”
02|背景导读
长寿研究(longevity research,研究如何延长健康生活并推迟衰老相关疾病)如今连接了消费者医疗服务、人工智能(artificial intelligence,AI)、制药、生物技术和资本市场。
原文报道的价格、融资和药企合作金额属于2026年11月3日报道时的口径,不宜直接当作当前报价或已兑现交易。医学部分尤其要区分“已有具体适应证的药物”和“尚未证实可以让健康人延寿的抗衰老技术”。
FDA公开说明,目前尚无药物被证实可以减缓或逆转人类衰老这一整体过程;与此同时,针对具体疾病获批的药物可能实实在在减少疾病风险,但这种收益不能无限扩大 。
本篇学习的核心阅读路径是:先理解长寿产业的两种商业模式;再识别全身筛查、NAD+与“生物年龄时钟”的证据局限;最后分析药企为什么把巨额资金投向GLP-1、肺纤维化药物和表观遗传重编程。读者不需要预先掌握医学知识,文中每遇到专业名词,都在相关句子的词汇或文化拓展中给出解释。
03|阅读前问题
1.为什么文章把今天的“长寿生意”分成两条路线:一条是面向消费者的长寿服务,另一条是通过临床试验推进的药物研发?二者最大的差别是什么?
2.全身 MRI(全身磁共振)、大量抽血检测和各种补充剂,为什么会让人产生“我正在积极延寿”的感觉?这种感觉和真正被证实的健康获益之间,有什么距离?
3.如果某项服务声称能让你的 biological age(生物年龄) 下降,它究竟说明了什么?又为什么不能直接等同于“你会活得更久”?
4.GLP-1 类药物已经在减重和代谢疾病治疗上取得成功,但为什么文章仍提醒我们:治疗某些疾病有效,不等于已经证明能让健康人长寿?
5.当企业宣布签下 “worth up to ...”(总价值最高可达……)的巨额合作时,我们应该怎样理解这类表述?它反映的是已经兑现的商业收入,还是对未来结果的预期?
04|原文|完整英文
标题|The quest for immortality has become serious business
小标题|The bloom of youth(青春的绽放;文章从商业服务转向研发前景的分节标题)
On a quiet street in the posh London neighbourhood of Chelsea resides HUM2N, a longevity clinic. Inside, a man in socks, gloves and a headband steps into a fridge-sized cabinet chilled to -110°C. A few minutes of “cryotherapy” leave him, by his own account, invigorated. Next door a woman lies in a hyperbaric chamber—a pressurised capsule resembling a small submarine—breathing pure oxygen. Other clients take intravenous drips of NAD+, a molecule that cells need to turn food into energy; or have their blood drawn, mixed with ozone and put back. A package of five sessions at the clinic costs £3,000 ($4,025).
The quest to live for ever has lately garnered new interest. Dario Amodei, boss of Anthropic, an artificial-intelligence lab, has suggested that his technology could raise the human lifespan to 150 years. Sam Altman, his counterpart at OpenAI, has put more than $180m into Retro Biosciences, a startup aiming to add ten healthy years to human life. The powerful beyond Silicon Valley are eager, too.
HUM2N’s clients range from bosses to athletes to patients in their 80s with chronic disease, says Mohammed Enayat, its founder. As the world ages, interest in living longer is seeping into the mainstream. Across the OECD, a club of mostly rich countries, nearly a fifth of people are aged 65 or over; by 2050 more than a quarter will be. One of the loudest evangelists is Bryan Johnson, a tech entrepreneur who hopes never to die. He has turned his regime into a Netflix documentary and a YouTube channel with more than 2m subscribers.
Two very different industries are looking to seize on the opportunity. The first is a colourful and lightly regulated group of clinics and online businesses selling supplements, scans and treatments of sometimes dubious efficacy. The second is slower moving but more consequential. Working in concert with the world’s biggest drugmakers, a crop of biotechs is developing medicines that might slow ageing itself—or even reverse it.
The prize is enormous. Pharma bosses long dismissed obesity as a niche market. GLP-1s proved them wrong, and made Eli Lilly the first drugmaker worth $1trn. A medicine that slowed ageing could be bigger still. “You can sell one year of life,” muses Alex Zhavoronkov, the founder of Insilico Medicine, an AI drug-discovery firm. “How much can you charge?”
The bloom of youth|青春的绽放
Such a drug may be years away, if it comes at all. Into the gap has rushed a business catering to the impatient, one that sits largely outside conventional health care. Insurers cover almost none of it, so customers pay in cash.
First comes measurement, on the belief that tracking everything will catch problems early enough to fix them. Providers offer blood tests, genome sequencing and full-body scans that promise to spot cancers or autoimmune disorders before symptoms appear. Prenuvo, one such firm, charges around $4,000 for an MRI scan of a patient’s entire body. Many sell annual subscriptions, retesting customers regularly to look for changes. Neko Health, a Swedish provider backed by Daniel Ek, a co-founder of Spotify, raised $700m in July ahead of its launch in America.
Next comes treatment. Much of that takes place in longevity clinics like HUM2N. Some estimates put the number of these at about 800 in America alone. The label is unregulated and vague, says Andrea Maier of the National University of Singapore, who co-founded a longevity clinic herself. At too many, she says, customers pick their own treatment, as though ordering pizza. “It’s not care.”
The most adventurous patients head to Roatán, an island off Honduras, where clinics offer gene therapy, stem-cell infusions and other experimental treatments. Others turn to social media, where a growing number of influencers peddle elixirs. Mr Johnson’s company, Blueprint, sells supplements, a powdered “longevity mix”—and olive oil. Then there are the many online businesses selling injectable “peptides”, including the “Wolverine stack”, a combination that is claimed to speed the repair of muscles and tendons.
Little of this rests on solid science. The American College of Radiology, a professional body, says there is “no documented evidence” that full-body screening is cost-effective or prolongs life. Such scans can lead to over-diagnosis, turning up harmless anomalies that prompt needless further tests. The treatments fare no better. Studies of NAD+ supplements have been inconclusive or shown limited effect. Peptides are a wild west, with vendors often labelling them as “for research use only” to dodge regulators.
In parallel, drugmakers are looking for scientifically proven ways to add healthy years—a far more arduous process. America’s Food and Drug Administration (FDA) does not treat ageing as a disease, so there is no route to approving a medicine that slows it. Would-be longevity drugs must instead win approval to treat a specific condition, often one linked to ageing, and then try to expand to others.
GLP-1s show how that might work. First approved for diabetes and then obesity, these drugs have since been shown to help with heart disease, sleep apnoea and kidney problems, all of which become more common with age. By lowering the risk of such conditions, the drugs may thus help people live longer. At a conference last month Lilly and Novo, its Danish rival, presented data suggesting that patients taking their GLP-1s were ageing more slowly. The yardstick was “ageing clocks”, which estimate how old a body really is (as opposed to how many birthdays it has had) from chemical marks on DNA or the mix of proteins in the blood. Novo found the biological age of the hearts of patients on its GLP-1s to be up to four years younger compared with those on a placebo, though all were overweight or diabetic. Lilly calls its own results preliminary.
Whatever GLP-1s turn out to do for ageing, they have already changed how big pharma thinks about the opportunity. Five or ten years ago drugmakers were chasing rare diseases, says Stephen Roper of L.E.K., a consultancy. But GLP-1s have re-established the appeal of mass-market drugs.
Rather than develop longevity treatments themselves, pharma giants mostly buy options on biotechs’ work. Lilly has struck a deal with Insilico worth up to $2.75bn. Novartis, a Swiss drugmaker, has one worth up to $550m with BioAge Labs, another biotech. The ranks of such startups are growing. Last year longevity biotechs raised $18.4bn, more than in the previous ten years combined (see chart).
Insilico calls its products “dual-purpose therapeutics”, each targeting ageing and a specific disease at the same time. A drug aimed only at ageing, argues Dr Zhavoronkov, its boss, would struggle to attract serious investors. Insilico’s most advanced candidate, rentosertib, treats idiopathic pulmonary fibrosis, a disease that scars the lungs. It entered a late-stage trial in July, making it one of the furthest along of any drug designed with ageing in mind. In an earlier trial of 42 patients, ageing clocks suggested that those on the drug were biologically younger than those on a placebo, by around three years on some measures, though all were already ill.
Other startups are looking to reverse ageing altogether. They include Mr Altman’s Retro; Altos Labs; and NewLimit, co-founded by Brian Armstrong, a crypto entrepreneur, which in June announced $435m in fresh funding. Most are betting on “epigenetic reprogramming”, the idea that the chemical switches on DNA, which become muddled with age, can be reset.
Previous efforts by drugmakers to create longevity treatments have ended in disappointment. In 2008 Britain’s GSK bought Sirtris, a biotech developing drugs inspired by resveratrol, a compound in red wine. Five years later it shut the firm down. Calico, launched by Google in 2013 to tackle ageing, has achieved little. Unity Biotechnology, a startup focused on clearing out ageing cells, laid off its entire staff in May last year after disappointing trials.
The new wave of biotech founders and investors argue this time will be different, thanks in part to AI, which they hope will accelerate discoveries. The first human trials for a drug targeting epigenetic reprogramming—a liver treatment developed by NewLimit—may begin next year. While the results are gathered, consumers will keep seeking immortality elsewhere.
05|内容简介
文章开头用一间伦敦长寿诊所的极低温舱、高压氧舱和NAD+注射服务制造画面感,转而指出资本正在同时押注两条路线:一条是监管相对宽松、直接面向消费者销售检测和疗法的市场,另一条是以疾病治疗为入口、尝试从生物机制延缓衰老的药物研发。
中段主要讨论全身MRI筛查、过度诊断、NAD+与实验性肽类的证据限制;随后用GLP-1药物、衰老时钟、肺纤维化药物和表观遗传重编程解释药企如何把长寿研究变成新的商业机会。结尾回顾失败案例,提醒读者:科技愿景很大,验证过程往往很长。
06|分段+分句精读
阅读方法|每段先展示英文段落,再逐句按“生词(IPA音标+文中义)→ 结构(主干主谓宾/主系表、从句层级、修饰关系和作用)→ 翻译”阅读。每个生词单独一行;每条结构说明也独立成行。短句适度简化,长难句分层解析。
标题|The quest for immortality has become serious business
生词:
quest /ˈkwest/:追寻;长期追求
immortality /ˌɪmɔːrˈtæləti/:不朽;永生(目前不是现实可实现的医疗结果)
serious business /ˈsɪriːəs ˈbɪznəs/:规模庞大、受到严肃投资关注的商业活动
结构:
主干:The quest for immortality(主语)+has become(现在完成时系动词)+serious business(表语)。
for immortality 是介词短语修饰 quest,限定追求目标;has become 强调近年发生的商业化趋势;serious business 双关“严肃事业”和“大生意”。
翻译:追求永生,如今已成为一门真正的大生意。
第一段|伦敦诊所:把“永生想象”卖成体验
网络图片 01|HUM2N 伦敦诊所:极低温治疗舱实景。HUM2N 官网展示其极低温舱设备。对应原文开头的低温体验场景;设备实景不能证明延寿功效。
本段原文|On a quiet street in the posh London neighbourhood of Chelsea resides HUM2N, a longevity clinic. Inside, a man in socks, gloves and a headband steps into a fridge-sized cabinet chilled to -110°C. A few minutes of “cryotherapy” leave him, by his own account, invigorated. Next door a woman lies in a hyperbaric chamber—a pressurised capsule resembling a small submarine—breathing pure oxygen. Other clients take intravenous drips of NAD+, a molecule that cells need to turn food into energy; or have their blood drawn, mixed with ozone and put back. A package of five sessions at the clinic costs £3,000 ($4,025).
01|On a quiet street in the posh London neighbourhood of Chelsea resides HUM2N, a longevity clinic.
生词:
posh /ˈpɑːʃ/:高档的;富裕阶层聚居的。
neighbourhood /ˈneɪbɚˌhʊd/:社区;街区。
resides /rɪˈzaɪdz/:坐落于(描写机构所在地)
longevity /lɑːnˈdʒevəti/:长寿;寿命延长研究或服务。
clinic /ˈklɪnɪk/:诊所。
结构:
主干(倒装句):HUM2N(主语)+resides(谓语:坐落)+on a quiet street(地点状语);原文把地点 On a quiet street... 提前,因此出现主谓倒装。
in the posh London neighbourhood of Chelsea 是地点后置限定,具体说明街道位于哪里;a longevity clinic 是 HUM2N 的同位语,解释这是什么机构。
翻译:在伦敦富裕的切尔西街区一条安静的街道上,坐落着一家名为HUM2N的长寿诊所。
02|Inside, a man in socks, gloves and a headband steps into a fridge-sized cabinet chilled to -110°C.
生词:
headband /ˈheˌdbænd/:头带。
fridge-sized /ˈfrɪdʒ ˈsaɪzd/:冰箱大小的。
cabinet /ˈkæbənət/:舱体;柜式设备。
chilled /ˈtʃɪld/:被冷却的。
结构:
主干:a man(主语)+steps into(谓语)+a fridge-sized cabinet(介词宾语);Inside 是地点状语。
in socks, gloves and a headband 修饰 a man,说明穿戴;chilled to -110°C 是过去分词后置定语,修饰 cabinet,等同于 which is chilled...。
翻译:诊所里,一个戴着袜子、手套和头带的男人走进一台冰箱大小、冷却至零下110摄氏度的舱体。
03|A few minutes of “cryotherapy” leave him, by his own account, invigorated.
生词:
cryotherapy /ˌkraɪoʊˈθerəpi/:冷冻疗法(利用低温的干预方式;不能直接等同于延寿)
by his own account /ˈbaɪ ˈhɪz ˈoʊn əˈkaʊnt/:据他本人所说(不是独立疗效证据)
invigorated /ˌɪˈnvɪɡɚˌeɪtɪd/:精神振奋的;感觉恢复活力的。
结构:
主干:A few minutes of cryotherapy(主语)+leave(谓语)+him(宾语)+invigorated(宾语补足语);属于 leave + 宾语 + 形容词结构。
by his own account 是插入性介词短语,限定‘精神焕发’是当事人的自述而非已证实的治疗效果。
翻译:据他自己描述,几分钟的‘冷冻疗法’让他精神焕发。
04|Next door a woman lies in a hyperbaric chamber—a pressurised capsule resembling a small submarine—breathing pure oxygen.
生词:
hyperbaric chamber /ˌhaɪpərˈbærɪk ˈtʃeɪmbər/:高压氧舱(在高于普通气压的环境中供氧的设备)
pressurised /pressurised/:加压的。
capsule /ˈkæpsəl/:舱体;密封容器。
resembling /rɪˈzembəlɪŋ/:形似;类似。
submarine /ˈsʌbmɚˌiːn/:潜艇。
pure oxygen /ˈpjʊr ˈɑːksədʒən/:纯氧。
结构:
主干:a woman(主语)+lies(谓语)+in a hyperbaric chamber(地点状语);Next door 是前置地点状语。
破折号之间 a pressurised capsule... 是同位解释,说明高压氧舱外形;resembling a small submarine 为现在分词定语修饰 capsule;breathing pure oxygen 为现在分词状语,补充女性躺着时的动作。
翻译:隔壁,一名女性躺在高压氧舱内——那是一个像小潜艇的加压舱——呼吸着纯氧。
05|Other clients take intravenous drips of NAD+, a molecule that cells need to turn food into energy; or have their blood drawn, mixed with ozone and put back.
生词:
clients /ˈklaɪənts/:客户;服务使用者。
intravenous drips /ˌɪntrəˈviːnəs drɪps/:静脉滴注。
NAD+ /ˌen eɪ ˈdiː plʌs/:烟酰胺腺嘌呤二核苷酸;参与细胞能量代谢的辅酶。
molecule /ˈmɑːləˌkjuːl/:分子。
their /ˈðer/:他们的;其。
blood drawn /ˈblʌd ˈdrɔːn/:抽血。
mixed with ozone /ˈmɪkst ˈwɪð ˈoʊˌzoʊn/:与臭氧混合(臭氧自体血疗法的描述)
结构:
并列主干一:Other clients(主语)+take(谓语)+intravenous drips of NAD+(宾语)。
a molecule that cells need to turn food into energy 是 NAD+ 的同位语;其中 that cells need... 是定语从句,cells(主语)+need(谓语)+that/该分子(宾语),to turn... 表用途。
并列主干二:Other clients(省略的主语)+have(使役谓语)+their blood(宾语)+drawn, mixed ... and put back(三个过去分词补语);have something done 表示‘让某物被处理’,不是顾客自己抽血。
翻译:其他顾客接受NAD+静脉滴注——这种分子参与细胞把食物转化为能量的过程;也有人抽出血液,与臭氧混合后再回输体内。
06|A package of five sessions at the clinic costs £3,000 ($4,025).
生词:
package /ˈpækədʒ/:疗程套餐。
sessions /ˈseʃənz/:单次疗程;服务次数。
clinic /ˈklɪnɪk/:诊所。
结构:
主干:A package of five sessions at the clinic(主语)+costs(谓语)+£3,000(金额宾语);of five sessions 和 at the clinic 都是主语名词短语的后置限定。
翻译:这家诊所五次疗程的套餐价格为3000英镑(约4025美元)。
第二段|科技资本:为何重新热衷长寿
网络图片 02|Anthropic 创始人达里奥·阿莫代伊的官方人物资料。
本段原文|The quest to live for ever has lately garnered new interest. Dario Amodei, boss of Anthropic, an artificial-intelligence lab, has suggested that his technology could raise the human lifespan to 150 years. Sam Altman, his counterpart at OpenAI, has put more than $180m into Retro Biosciences, a startup aiming to add ten healthy years to human life. The powerful beyond Silicon Valley are eager, too.
07|The quest to live for ever has lately garnered new interest.
生词:
quest /ˈkwest/:追寻;长期探索。
for ever /ˈfɔːr ˈevɚ/:永远;永久。
has lately garnered /ˈhæz ˈleɪtliː ˈɡɑːrnɚd/:近来获得;近来引起。
结构:
主干:The quest to live for ever(主语)+has garnered(现在完成时谓语)+new interest(宾语);lately 是时间状语,突出近期趋势。
to live for ever 是不定式后置定语,修饰 quest(追求什么);has garnered 表示过去开始的关注延续到现在。
翻译:近来,人们对追求永生重新产生了兴趣。
08|Dario Amodei, boss of Anthropic, an artificial-intelligence lab, has suggested that his technology could raise the human lifespan to 150 years.
生词:
Dario Amodei /ˈdɑːrioʊ əˈmoʊdeɪ/:达里奥·阿莫代伊(Anthropic负责人)
artificial-intelligence lab /ˌɑːrtəˈfɪʃəl ˌɪˈntelədʒəns ˈlæb/:人工智能实验室。
suggested /səˈdʒestɪd/:提出;暗示(并非已证实)
lifespan /ˈlaɪfˌspæn/:寿命长度。
years /ˈjɪrz/:年;年数。
结构:
主干:Dario Amodei(主语)+has suggested(谓语)+that...(宾语从句)。
boss of Anthropic 与 an artificial-intelligence lab 是两层同位语,分别解释人物身份和公司性质;宾语从句内部:his technology(主语)+could raise(谓语)+the human lifespan(宾语)+to 150 years(结果补语);could 表可能性而非事实。
翻译:人工智能公司Anthropic的负责人达里奥·阿莫代伊曾提出,他的技术可能将人类寿命提升至150岁。
09|Sam Altman, his counterpart at OpenAI, has put more than $180m into Retro Biosciences, a startup aiming to add ten healthy years to human life.
生词:
counterpart /ˈkaʊntɚˌpɑːrt/:职位相当的人;对应人物。
startup /ˈstɑːˌrtʌp/:初创企业。
healthy years /ˈhelθiː ˈjɪrz/:健康生活年数(健康寿命)
结构:
主干:Sam Altman(主语)+has put(谓语)+more than $180m(宾语)+into Retro Biosciences(去向状语)。
his counterpart at OpenAI 是 Sam Altman 同位语;a startup aiming to add... 是 Retro Biosciences 同位语,其中 aiming to add... 为现在分词短语修饰 startup,to add ten healthy years ... 是目标。
翻译:OpenAI的萨姆·奥尔特曼已向Retro Biosciences投入超过1.8亿美元;这家初创公司致力于为人类增加十年健康寿命。
10|The powerful beyond Silicon Valley are eager, too.
生词:
the powerful /ðə ˈpaʊɚfəl/:有权势或影响力的人。
beyond /bɪˈɑːnd/:超出;在……之外。
Silicon Valley /ˈsɪləkən ˈvæliː/:硅谷(美国科技创业中心)
结构:
主干:The powerful(主语,the + 形容词泛指‘有权势的人’)+are(系动词)+eager(表语);beyond Silicon Valley 限定主语群体,too 表‘也’。
翻译:硅谷之外的权势人物同样跃跃欲试。
第三段|老龄化与网红长寿生活方式
网络图片 03|布莱恩·约翰逊的抗衰老生活方式影像。
本段原文|HUM2N’s clients range from bosses to athletes to patients in their 80s with chronic disease, says Mohammed Enayat, its founder. As the world ages, interest in living longer is seeping into the mainstream. Across the OECD, a club of mostly rich countries, nearly a fifth of people are aged 65 or over; by 2050 more than a quarter will be. One of the loudest evangelists is Bryan Johnson, a tech entrepreneur who hopes never to die. He has turned his regime into a Netflix documentary and a YouTube channel with more than 2m subscribers.
11|HUM2N’s clients range from bosses to athletes to patients in their 80s with chronic disease, says Mohammed Enayat, its founder.
生词:
clients /ˈklaɪənts/:客户;服务使用者。
range from /ˈreɪndʒ ˈfrʌm/:范围从……到……。
athletes /ˈæˌθliːts/:运动员。
their /ˈðer/:他们的;其。
chronic disease /ˈkrɑːnɪk dɪˈziːz/:慢性疾病(长期存在、需管理的健康问题)
结构:
被引述内容的主干:HUM2N’s clients(主语)+range(谓语)+from bosses to athletes to patients...(范围补语);连续 from...to...to... 枚举客户层次。
says Mohammed Enayat 为报道的引语后置结构;its founder 是 Mohammed Enayat 同位语;in their 80s 和 with chronic disease 都修饰 patients。
翻译:创始人穆罕默德·埃纳亚特说,HUM2N的客户从企业高管、运动员到患有慢性病的八十多岁老人都有。
12|As the world ages, interest in living longer is seeping into the mainstream.
生词:
world /ˈwɝld/:世界;世界人口(原文指全球人口总体)
seeping into /ˈsiːpɪŋ ˈɪntuː/:逐步渗透进入。
mainstream /ˈmeɪnsˌtriːm/:主流;大众市场。
结构:
主干:interest in living longer(主语)+is seeping(现在进行时谓语)+into the mainstream(方向状语)。
As the world ages 是时间兼背景状语从句:the world(主语)+ages(谓语);in living longer 为介词短语修饰 interest;seep into 比喻‘慢慢渗透’,强调渐进过程。
翻译:随着世界人口老龄化,延长寿命的兴趣正在逐步进入大众视野。
13|Across the OECD, a club of mostly rich countries, nearly a fifth of people are aged 65 or over; by 2050 more than a quarter will be.
生词:
OECD /ˌoʊ iː siː ˈdiː/:经济合作与发展组织(主要由高收入经济体组成)
nearly a fifth /ˈnɪrliː ə ˈfɪfθ/:接近五分之一。
aged 65 or over /ˈeɪdʒd 65 ˈɔːr ˈoʊvɚ/:65岁及以上。
a quarter /ə ˈkwɔːrtər/:四分之一。
will be /ˈwɪl ˈbiː/:将会是;将处于某种状态。
结构:
分号前主干:nearly a fifth of people(主语)+are(系动词)+aged 65 or over(表语);Across the OECD 是范围状语。
a club of mostly rich countries 是 OECD 的同位解释;分号后 by 2050 是时间状语,more than a quarter(主语)+will be(谓语),省略 aged 65 or over,避免重复。
翻译:在经合组织国家,近五分之一人口已达65岁及以上;到2050年,这一比例将超过四分之一。
14|One of the loudest evangelists is Bryan Johnson, a tech entrepreneur who hopes never to die.
生词:
evangelists /ɪˈvændʒəlɪsts/:热情倡导者;积极推广者。
entrepreneur /ˌɑːntrəprəˈnɝ/:创业者;企业家。
loudest /ˈlaʊdəst/:原文实词;结合语境识别具体意义。
结构:
主干:One of the loudest evangelists(主语)+is(系动词)+Bryan Johnson(表语)。
a tech entrepreneur 是 Bryan Johnson 的同位语;who hopes never to die 为定语从句,修饰 entrepreneur,who(主语)+hopes(谓语)+never to die(不定式宾语)。
翻译:最积极的倡导者之一,是希望永远不死的科技创业者布莱恩·约翰逊。
15|He has turned his regime into a Netflix documentary and a YouTube channel with more than 2m subscribers.
生词:
regime /rəˈʒiːm/:系统化的生活方案;严格执行的习惯。
subscribers /səbsˈkraɪbɚz/:订阅者。
turned /ˈtɝnd/:原文实词;结合语境识别具体意义。
结构:
主干:He(主语)+has turned(谓语)+his regime(宾语)+into a Netflix documentary and a YouTube channel(结果/转化补语)。
with more than 2m subscribers 为介词短语后置修饰 a YouTube channel;现在完成时强调方案商业化的现状。
翻译:他把自己的养生方案做成了Netflix纪录片,还经营着拥有超过200万订阅者的YouTube频道。
第四段|两种产业,两套证据逻辑
本段原文|Two very different industries are looking to seize on the opportunity. The first is a colourful and lightly regulated group of clinics and online businesses selling supplements, scans and treatments of sometimes dubious efficacy. The second is slower moving but more consequential. Working in concert with the world’s biggest drugmakers, a crop of biotechs is developing medicines that might slow ageing itself—or even reverse it.
16|Two very different industries are looking to seize on the opportunity.
生词:
different /ˈdɪfɚənt/:不同的;有差异的。
seize on /ˈsiːz ˈɑːn/:抓住并利用机会。
industries /ˈɪndəstriːz/:原文实词;结合语境识别具体意义。
结构:
主干:Two very different industries(主语)+are looking(谓语)+to seize on the opportunity(不定式补足语/目的);seize on 表‘抓住并利用’。
翻译:两类截然不同的产业正试图抓住这一机遇。
17|The first is a colourful and lightly regulated group of clinics and online businesses selling supplements, scans and treatments of sometimes dubious efficacy.
生词:
first /ˈfɝst/:首先;第一步。
lightly regulated /ˈlaɪtliː ˈreɡjəˌleɪtɪd/:监管相对宽松的。
supplements /ˈsʌpləmənts/:膳食补充剂。
scans /ˈskænz/:扫描检查;影像检查。
treatments /ˈtriːtmənts/:治疗项目;干预措施。
dubious efficacy /ˈduːbiːəs ˈefɪˌkæsiː/:疗效存疑(尚缺可靠证据)
结构:
主干:The first(主语,指第一类产业)+is(系动词)+a ... group of clinics and online businesses(表语)。
colourful and lightly regulated 为并列前置定语;selling supplements, scans and treatments 为现在分词定语,修饰 businesses/group;of sometimes dubious efficacy 具体限定 treatments(也可语义上涉及这些商品和服务),说明有效性存疑。
翻译:第一类是色彩斑斓、监管相对宽松的诊所和线上商家,出售疗效有时值得怀疑的补充剂、扫描服务与治疗方案。
18|The second is slower moving but more consequential.
生词:
second /ˈsekənd/:第二类(指药企与生物科技研发)
slower /ˈsloʊɚ/:发展较慢的。
consequential /ˌkɑːnsəˈkwenʃəl/:影响深远的;后果重大的。
结构:
主干:The second(主语)+is(系动词)+slower moving but more consequential(并列表语);but 对比发展速度与影响大小。
翻译:第二类行动更慢,但影响更深远。
19|Working in concert with the world’s biggest drugmakers, a crop of biotechs is developing medicines that might slow ageing itself—or even reverse it.
生词:
working in concert with /ˈwɝkɪŋ ɪn ˈkɑːnsɚt ˈwɪð/:与……协同合作。
world /ˈwɝld/:世界;世界人口(原文指全球人口总体)
biotechs /ˈbaɪoʊˌteks/:生物科技企业。
slow ageing /ˈsloʊ ageing/:减缓衰老(尚待科学验证)
结构:
主干:a crop of biotechs(主语)+is developing(谓语)+medicines(宾语)。
Working in concert with the world’s biggest drugmakers 是句首现在分词状语,说明研发时的合作方式;that might slow ageing itself—or even reverse it 为定语从句修饰 medicines:that(主语)+might slow/reverse(谓语)+ageing/it(宾语),might 表尚未证实的潜在能力。
翻译:一批生物科技公司正与全球大型药企合作,研发可能减缓衰老本身、甚至逆转衰老的药物。
第五段|最诱人的商业回报
本段原文|The prize is enormous. Pharma bosses long dismissed obesity as a niche market. GLP-1s proved them wrong, and made Eli Lilly the first drugmaker worth $1trn. A medicine that slowed ageing could be bigger still. “You can sell one year of life,” muses Alex Zhavoronkov, the founder of Insilico Medicine, an AI drug-discovery firm. “How much can you charge?”
20|The prize is enormous.
生词:
prize /ˈpraɪz/:回报;商业大奖(原文借指潜在市场规模)
enormous /ɪˈnɔːrməs/:极其庞大的。
结构:
主干:The prize(主语,这里比喻潜在商业回报)+is(系动词)+enormous(表语)。
翻译:这个商业机会极其庞大。
21|Pharma bosses long dismissed obesity as a niche market.
生词:
pharma /ˈfɑːrmə/:制药行业。
obesity /oʊˈbiːsətiː/:肥胖症。
niche market /ˈnɪtʃ ˈmɑːrkət/:小众市场。
结构:
主干:Pharma bosses(主语)+dismissed(谓语)+obesity(宾语)+as a niche market(宾语补足语);dismiss A as B 表‘把A看作不重要的B’。
翻译:制药企业的负责人曾长期把肥胖症视为一个小众市场。
22|GLP-1s proved them wrong, and made Eli Lilly the first drugmaker worth $1trn.
生词:
GLP-1s /ˌdʒiː el ˌpiː ˈwʌnz/:GLP-1类药物(胰高血糖素样肽-1相关药物;部分具有明确治疗适应证)
proved /ˈpruːvd/:证明;使原先的判断被推翻。
Lilly /ˈlɪli/:礼来(制药企业)
first /ˈfɝst/:首先;第一步。
worth $1trn /ˈwɝθ $1trn/:市值达一万亿美元。
结构:
主干:GLP-1s(主语)+proved(谓语一)+them(宾语)+wrong(宾补),and+made(谓语二)+Eli Lilly(宾语)+the first drugmaker...(宾补)。
worth $1trn 是后置形容词短语,修饰 drugmaker,指估值规模;and 并列两个结果:推翻市场判断与改变企业估值。
翻译:GLP-1类药物证明他们判断错误,并使礼来成为首家市值达到一万亿美元的制药企业。
23|A medicine that slowed ageing could be bigger still.
生词:
medicine /ˈmedəsən/:药物。
slowed /ˈsloʊd/:减缓;放慢。
ageing /ageing/:衰老(随时间出现的生理变化)
结构:
主干:A medicine(主语)+could be(系动词)+bigger still(表语)。
that slowed ageing 是定语从句,修饰 medicine,其中 that 作主语、slowed 作谓语、ageing 作宾语;这里是假设性设想,不代表药物已经问世。
翻译:如果有一种药能减缓衰老,它的市场可能还要大。
24|“You can sell one year of life,” muses Alex Zhavoronkov, the founder of Insilico Medicine, an AI drug-discovery firm.
生词:
muses /ˈmjuːzəz/:沉思地说;设想。
medicine /ˈmedəsən/:药物。
AI drug-discovery /ˌeɪ ˈaɪ drʌɡ dɪˈskʌvəri/:人工智能辅助药物发现。
结构:
引语主干:You(主语)+can sell(谓语)+one year of life(宾语)。
muses Alex Zhavoronkov 为引语后置的倒装报道语(正常语序 Alex Zhavoronkov muses);the founder of Insilico Medicine 和 an AI drug-discovery firm 是两层同位解释;muses 表‘沉思、设想’,不是已经定价。
翻译:‘你可以出售一年的寿命。’人工智能药物研发企业英矽智能创始人亚历克斯·扎沃龙科夫这样设想。
25|“How much can you charge?”
生词:
how much /ˈhaʊ ˈmʌtʃ/:多少;问价格或数量的疑问表达。
charge /ˈtʃɑːrdʒ/:收费;索价。
结构:
主干:How much(疑问宾语/金额)+can(情态动词)+you(主语)+charge(谓语);疑问词前置引出商业定价问题。
翻译:‘那你能收多少钱呢?’
第六段|青春之花:商业服务涌入技术空档
本段原文|Such a drug may be years away, if it comes at all. Into the gap has rushed a business catering to the impatient, one that sits largely outside conventional health care. Insurers cover almost none of it, so customers pay in cash.
26|Such a drug may be years away, if it comes at all.
生词:
years /ˈjɪrz/:年;年数。
if it comes at all /ˈɪf ˈɪt ˈkʌmz ˈæt ˈɔːl/:倘若最终真的出现(极强不确定性)
结构:
主干:Such a drug(主语)+may be(谓语)+years away(表语);may 表不确定性。
if it comes at all 是省略型条件状语从句,表示‘如果它终究能够出现’,进一步降低确定性,避免把研究前景误读为承诺。
翻译:这样的药物也许还要很多年才会出现——如果最终真的出现的话。
27|Into the gap has rushed a business catering to the impatient, one that sits largely outside conventional health care.
生词:
into the gap /ˈɪntuː ðə ˈɡæp/:进入市场空白。
catering to /ˈkeɪtɚɪŋ ˈtuː/:迎合……需求;为……提供服务。
impatient /ˌɪˈmpeɪʃənt/:急切的;等不及的。
conventional health care /kəˈnvenʃənəl ˈhelθ ˈker/:常规医疗照护体系。
结构:
主干(地点/方向提前导致完全倒装):a business(主语)+has rushed(谓语)+into the gap(方向状语);原文语序为 Into the gap has rushed a business。
catering to the impatient 为现在分词定语修饰 business;one that sits largely outside... 是同位语,that 引导定语从句:that(主语)+sits(谓语)+outside conventional health care(地点/范围补语)。
翻译:一种面向急切消费者的商业模式涌入了这个空档,而它在很大程度上游离于传统医疗体系之外。
28|Insurers cover almost none of it, so customers pay in cash.
生词:
insurers /ˌɪˈnʃʊrɚz/:保险公司。
customers /ˈkʌstəmɚz/:消费者;顾客。
pay in cash /ˈpeɪ ɪn ˈkæʃ/:自费支付(此处强调不经医保报销)
结构:
前一分句主干:Insurers(主语)+cover(谓语)+almost none of it(宾语)。
so 引出结果分句:customers(主语)+pay(谓语)+in cash(方式状语);so 的逻辑关系是‘保险不覆盖→顾客支付’。
翻译:保险公司几乎不报销这些服务,因此客户只能自费。
第七段|全面检测真的能早发现问题吗
本段原文|First comes measurement, on the belief that tracking everything will catch problems early enough to fix them. Providers offer blood tests, genome sequencing and full-body scans that promise to spot cancers or autoimmune disorders before symptoms appear. Prenuvo, one such firm, charges around $4,000 for an MRI scan of a patient’s entire body. Many sell annual subscriptions, retesting customers regularly to look for changes. Neko Health, a Swedish provider backed by Daniel Ek, a co-founder of Spotify, raised $700m in July ahead of its launch in America.
29|First comes measurement, on the belief that tracking everything will catch problems early enough to fix them.
生词:
first /ˈfɝst/:首先;第一步。
measurement /ˈmeʒɚmənt/:测量;检测环节。
tracking /ˈtrækɪŋ/:持续追踪监测。
结构:
主干(倒装):measurement(主语)+comes(谓语);First 提前,构成 First comes measurement,用于列举商业流程。
on the belief that... 解释做此类检测的信念;that 后为同位语从句,tracking everything(动名词主语)+will catch(谓语)+problems(宾语);early enough to fix them 使用 enough to do 结构说明早发现的目的。
翻译:首先是测量:他们相信追踪足够多的指标,就能足够早地发现并解决问题。
30|Providers offer blood tests, genome sequencing and full-body scans that promise to spot cancers or autoimmune disorders before symptoms appear.
生词:
blood tests /ˈblʌd ˈtests/:血液检测。
genome sequencing /ˈdʒiːnoʊm ˈsiːkwənsɪŋ/:基因组测序(分析遗传物质的序列)
full-body scans /ˈfʊl ˈbɑːdiː ˈskænz/:全身扫描(非特定疾病筛查手段)
autoimmune disorders /ˌɔːˈtɔɪmjuːn dɪˈsɔːrdɚz/:自身免疫性疾病(免疫系统错误攻击自身组织)
before symptoms appear /bɪˈfɔːr ˈsɪmptəmz əˈpɪr/:在出现症状之前。
结构:
主干:Providers(主语)+offer(谓语)+blood tests, genome sequencing and full-body scans(三项并列宾语)。
that promise to spot... 是定语从句,主要修饰 full-body scans,也承接整组筛查服务的营销承诺;to spot cancers or autoimmune disorders 是 promise 的不定式宾语;before symptoms appear 为时间状语从句。
翻译:商家提供血液检测、基因组测序和全身扫描,承诺在癌症或自身免疫疾病出现症状前就发现它们。
31|Prenuvo, one such firm, charges around $4,000 for an MRI scan of a patient’s entire body.
生词:
Prenuvo /prəˈnuːvoʊ/:Prenuvo(全身MRI筛查服务企业)
MRI scan /ˌem ɑːr ˈaɪ skæn/:磁共振成像扫描(利用磁场与射频成像)
charges /ˈtʃɑːrdʒəz/:原文实词;结合语境识别具体意义。
结构:
主干:Prenuvo(主语)+charges(谓语)+around $4,000(金额宾语)+for an MRI scan...(服务对象)。
one such firm 是 Prenuvo 的同位语;of a patient’s entire body 修饰 MRI scan,界定扫描范围。
翻译:此类企业Prenuvo对一次全身MRI扫描收费约4000美元。
32|Many sell annual subscriptions, retesting customers regularly to look for changes.
生词:
annual subscriptions /ˈænjuːəl səbsˈkrɪpʃənz/:年度订阅服务。
retesting /riːˈtestɪŋ/:定期复测。
customers /ˈkʌstəmɚz/:消费者;顾客。
结构:
主干:Many(主语,指许多服务商)+sell(谓语)+annual subscriptions(宾语)。
retesting customers regularly 是现在分词状语,补充订阅的实施方式;to look for changes 是目的不定式,说明重复检测的目标。
翻译:许多企业出售年度订阅服务,定期复查客户,以观察身体指标的变化。
33|Neko Health, a Swedish provider backed by Daniel Ek, a co-founder of Spotify, raised $700m in July ahead of its launch in America.
生词:
provider /prəˈvaɪdɚ/:服务提供者。
backed by /ˈbækt ˈbaɪ/:获得……支持或投资。
raised $700m /ˈreɪzd $700m/:融资七亿美元。
ahead of its launch /əˈhed ˈʌv ˈɪts ˈlɔːntʃ/:在进入市场之前。
结构:
主干:Neko Health(主语)+raised(谓语)+$700m(宾语)+in July(时间状语)。
a Swedish provider 是主语同位语;backed by Daniel Ek 为过去分词后置定语修饰 provider;a co-founder of Spotify 是 Daniel Ek 同位语;ahead of its launch in America 为时间关系状语。
翻译:由Spotify联合创始人丹尼尔·埃克支持的瑞典企业Neko Health,在进入美国市场前于7月融资7亿美元。
第八段|为何不能像点披萨一样选治疗
本段原文|Next comes treatment. Much of that takes place in longevity clinics like HUM2N. Some estimates put the number of these at about 800 in America alone. The label is unregulated and vague, says Andrea Maier of the National University of Singapore, who co-founded a longevity clinic herself. At too many, she says, customers pick their own treatment, as though ordering pizza. “It’s not care.”
34|Next comes treatment.
生词:
comes /ˈkʌmz/:原文实词;结合语境识别具体意义。
treatment /ˈtriːtmənt/:原文实词;结合语境识别具体意义。
结构:
主干(倒装列举):treatment(主语)+comes(谓语);Next 前置表示步骤排序,对应前段 First comes measurement。
翻译:接下来是治疗。
35|Much of that takes place in longevity clinics like HUM2N.
生词:
takes place /ˈteɪks ˈpleɪs/:发生;进行。
longevity /lɑːnˈdʒevəti/:长寿;寿命延长研究或服务。
clinics /ˈklɪnɪks/:原文实词;结合语境识别具体意义。
结构:
主干:Much of that(主语)+takes place(谓语短语)+in longevity clinics(地点状语);like HUM2N 是介词短语,举例说明诊所类别。
翻译:其中许多治疗在HUM2N这样的长寿诊所进行。
36|Some estimates put the number of these at about 800 in America alone.
生词:
estimates /ˈestəməts/:估算;预测数据。
number /ˈnʌmbɚ/:数量。
these /ˈðiːz/:原文实词;结合语境识别具体意义。
结构:
主干:Some estimates(主语)+put(谓语)+the number of these(宾语)+at about 800(宾补/估算值)。
in America alone 是范围状语,alone 强调‘仅美国’而非全球。
翻译:有估计认为,仅美国就有大约800家此类诊所。
37|The label is unregulated and vague, says Andrea Maier of the National University of Singapore, who co-founded a longevity clinic herself.
生词:
unregulated /əˈnreɡjəˌleɪtɪd/:缺乏专门监管的。
vague /ˈveɪɡ/:模糊的;边界不清的。
co-founded /ˈkoʊ ˈfaʊndɪd/:共同创办。
longevity /lɑːnˈdʒevəti/:长寿;寿命延长研究或服务。
clinic /ˈklɪnɪk/:诊所。
结构:
引述内容主干:The label(主语)+is(系动词)+unregulated and vague(并列表语)。
says Andrea Maier... 为引语后置结构;of the National University of Singapore 补充所属机构;who co-founded a longevity clinic herself 为非限制性定语从句,修饰 Andrea Maier,说明其亲身经历。
翻译:新加坡国立大学的安德烈娅·迈尔认为,‘长寿诊所’的定义既缺少监管,也相当模糊;她本人也联合创办过一家长寿诊所。
38|At too many, she says, customers pick their own treatment, as though ordering pizza.
生词:
customers /ˈkʌstəmɚz/:消费者;顾客。
their /ˈðer/:他们的;其。
ordering pizza /ˈɔːrdɚɪŋ ˈpiːtsə/:像点披萨一样选择(讽刺性比喻)
结构:
主干:customers(主语)+pick(谓语)+their own treatment(宾语)。
At too many(clinics省略)是地点/范围状语;she says 是插入性报道语;as though ordering pizza 是方式状语中的省略结构,完整意为 as though they were ordering pizza,构成讽刺性类比。
翻译:她说,在太多这样的诊所里,顾客像点披萨一样自行挑选治疗项目。
39|“It’s not care.”
生词:
It’s not care /ˈɪt ˈes ˈnɑːt ˈker/:这不是真正的医疗照护(原文直接批评)
结构:
主干:It(主语,指消费者自由选择的服务方式)+is not(系动词否定)+care(表语);短句使用强否定形成批判。
翻译:‘这并不是真正的医疗照护。’
第九段|社交媒体与试验性疗法
本段原文|The most adventurous patients head to Roatán, an island off Honduras, where clinics offer gene therapy, stem-cell infusions and other experimental treatments. Others turn to social media, where a growing number of influencers peddle elixirs. Mr Johnson’s company, Blueprint, sells supplements, a powdered “longevity mix”—and olive oil. Then there are the many online businesses selling injectable “peptides”, including the “Wolverine stack”, a combination that is claimed to speed the repair of muscles and tendons.
40|The most adventurous patients head to Roatán, an island off Honduras, where clinics offer gene therapy, stem-cell infusions and other experimental treatments.
生词:
adventurous /æˈdventʃɚəs/:敢于冒险的。
gene therapy /ˈdʒiːn ˈθerəpiː/:基因治疗(通过改变遗传物质治疗特定疾病的方式)
stem-cell infusions /ˈstem ˈsel ˌɪnˈfjuːʒənz/:干细胞输注。
experimental treatments /ɪkˌsperɪˈmentəl ˈtriːtmənts/:实验性治疗(安全有效性尚未完全确认)
结构:
主干:The most adventurous patients(主语)+head(谓语)+to Roatán(方向状语)。
an island off Honduras 是 Roatán 的同位语;where clinics offer... 为非限制性定语从句修饰 island,内部主干是 clinics(主语)+offer(谓语)+gene therapy, stem-cell infusions...(宾语)。
翻译:最愿意冒险的患者前往洪都拉斯近海的罗阿坦岛,当地诊所提供基因疗法、干细胞输注及其他实验性治疗。
41|Others turn to social media, where a growing number of influencers peddle elixirs.
生词:
growing /ˈɡroʊɪŋ/:不断增加;壮大。
number /ˈnʌmbɚ/:数量。
influencers /influencers/:网络影响者;网红。
peddle /ˈpedəl/:兜售(常带贬义)
elixirs /ɪˈlɪksɚz/:神奇药水;所谓长生灵药。
结构:
主干:Others(主语)+turn to(谓语)+social media(宾语)。
where a growing number... 为非限制性定语从句修饰 social media,内部主干 influencers(主语)+peddle(谓语)+elixirs(宾语)。
翻译:另一些人转向社交媒体,越来越多的网红在那里兜售所谓的‘长生灵药’。
42|Mr Johnson’s company, Blueprint, sells supplements, a powdered “longevity mix”—and olive oil.
生词:
supplements /ˈsʌpləmənts/:膳食补充剂。
powdered /ˈpaʊdɚd/:粉状的。
longevity mix /lɑːnˈdʒevəti mɪks/:长寿混合物(商业产品名称)
结构:
主干:Mr Johnson’s company, Blueprint(主语及同位语)+sells(谓语)+supplements, a powdered longevity mix and olive oil(并列宾语)。
破折号前的 and olive oil 单独强调商品清单中令人意外的橄榄油。
翻译:约翰逊的Blueprint公司出售补充剂、粉状‘长寿混合物’,甚至橄榄油。
43|Then there are the many online businesses selling injectable “peptides”, including the “Wolverine stack”, a combination that is claimed to speed the repair of muscles and tendons.
生词:
Wolverine stack /ˈwʊlvəriːn stæk/:“金刚狼组合”(商业俗称,非标准获批药物名称)
claimed to /ˈkleɪmd ˈtuː/:被宣称可以……(非证实)
tendons /ˈtendənz/:肌腱。
结构:
主干(there be结构):there(引导词)+are(谓语)+the many online businesses(真正主语)。
selling injectable peptides 为现在分词定语修饰 businesses;including the Wolverine stack 为举例的非谓语补充;a combination that is claimed... 是同位解释,that 引导定语从句修饰 combination。
is claimed to speed ... 为被动报告结构,意为‘被宣称具有某作用’,并非已经获得临床证实。
翻译:还有许多线上商家出售可注射‘肽类’产品,其中包括号称能促进肌肉与肌腱修复的‘金刚狼组合’。
第十段|证据审视:扫描、NAD+、肽类
本段原文|Little of this rests on solid science. The American College of Radiology, a professional body, says there is “no documented evidence” that full-body screening is cost-effective or prolongs life. Such scans can lead to over-diagnosis, turning up harmless anomalies that prompt needless further tests. The treatments fare no better. Studies of NAD+ supplements have been inconclusive or shown limited effect. Peptides are a wild west, with vendors often labelling them as “for research use only” to dodge regulators.
44|Little of this rests on solid science.
生词:
rests on /ˈrests ˈɑːn/:以……为基础。
solid science /ˈsɑːləd ˈsaɪəns/:可靠科学证据。
Little /ˈlɪtəl/:原文实词;结合语境识别具体意义。
结构:
主干:Little of this(主语)+rests on(谓语短语)+solid science(介词宾语);Little 含否定量,表示‘几乎没有’,为后文列举质疑做铺垫。
翻译:这些做法几乎没有多少建立在扎实的科学证据上。
45|The American College of Radiology, a professional body, says there is “no documented evidence” that full-body screening is cost-effective or prolongs life.
生词:
American College of Radiology /əˈmerəkən ˈkɑːlɪdʒ ˈʌv ˌreɪdiːˈɑːlədʒiː/:美国放射学会(影像医学专业学术组织)
documented evidence /ˈdɑːkjəˌmentəd ˈevədəns/:有文献证实的证据。
cost-effective /ˈkɑːst ɪˈfektɪv/:有成本效益的(收益相对于成本较好)
prolongs life /prəˈlɔːŋz ˈlaɪf/:延长寿命。
结构:
主干:The American College of Radiology(主语)+says(谓语)+[there is no documented evidence...](宾语从句)。
a professional body 为机构同位语;引述内容存在 there be 句型:there is no documented evidence;that full-body screening is cost-effective or prolongs life 为修饰 evidence 的同位语从句,具体解释缺乏哪种证据。
两个并列谓语 is cost-effective / prolongs life 分别对应经济性与生存收益,二者不应混同。
翻译:美国放射学会表示,尚无成文证据显示全身筛查具有成本效益或能够延长寿命。
46|Such scans can lead to over-diagnosis, turning up harmless anomalies that prompt needless further tests.
生词:
scans /ˈskænz/:扫描检查;影像检查。
over-diagnosis /ˈoʊvɚ ˌdaɪəˈɡnoʊsəs/:过度诊断(发现不会危害健康的异常并导致过度干预)
anomalies /əˈnɑːməliːz/:异常发现;异常指标。
needless /ˈniːdləs/:不必要的。
further tests /ˈfɝðɚ ˈtests/:追加检查。
结构:
主干:Such scans(主语)+can lead to(谓语)+over-diagnosis(介词宾语);can 表风险可能性。
turning up harmless anomalies 是现在分词结果状语,说明扫描如何引出过度诊断;that prompt needless further tests 为定语从句修饰 anomalies:that(主语)+prompt(谓语)+further tests(宾语)。
翻译:这类扫描可能引发过度诊断:发现无害异常,却导致不必要的进一步检查。
47|The treatments fare no better.
生词:
treatments /ˈtriːtmənts/:治疗项目;干预措施。
fare no better /ˈfer ˈnoʊ ˈbetɚ/:表现也好不到哪里去。
结构:
主干:The treatments(主语)+fare(谓语)+no better(比较状语/补语);fare 意为‘表现如何’,比较对象是上文缺乏证据的扫描项目。
翻译:这些治疗项目的证据表现也好不到哪里去。
48|Studies of NAD+ supplements have been inconclusive or shown limited effect.
生词:
NAD+ /ˌen eɪ ˈdiː plʌs/:烟酰胺腺嘌呤二核苷酸;参与细胞能量代谢的辅酶。
supplements /ˈsʌpləmənts/:膳食补充剂。
inconclusive /ˌɪnkənˈkluːsɪv/:结论不明确的;尚不能确认的。
limited effect /ˈlɪmətəd ɪˈfekt/:作用有限。
结构:
主干:Studies of NAD+ supplements(主语)+have been(系动词)+inconclusive(表语)or+have shown(谓语)+limited effect(宾语)。
现在完成时概括截至报道时的证据;inconclusive 与 limited effect 区分‘无法下结论’和‘收益有限’。
翻译:有关NAD+补充剂的研究结论尚不明确,或者只发现了有限效果。
49|Peptides are a wild west, with vendors often labelling them as “for research use only” to dodge regulators.
生词:
wild west /ˈwaɪld ˈwest/:“无法地带”(比喻市场监管混乱)
for research use only /ˈfɔːr riːˈsɝtʃ ˈjuːs ˈoʊnliː/:仅供研究使用(标签不代表人体使用安全)
dodge regulators /ˈdɑːdʒ ˈreɡjəˌleɪtɚz/:逃避监管。
结构:
主干一:Peptides(主语,泛指该类市场产品)+are(系动词)+a wild west(表语,比喻监管混乱)。
with vendors often labelling them... 是 with + 名词 + 现在分词复合结构,补充这种乱象的具体表现;them 指 peptides;as for research use only 为宾补;to dodge regulators 是目的不定式,说明贴标签的意图。
翻译:肽类产品市场鱼龙混杂,卖家常贴上‘仅供研究’标签来规避监管。
第十一段|药品监管:先治疗具体疾病
本段原文|In parallel, drugmakers are looking for scientifically proven ways to add healthy years—a far more arduous process. America’s Food and Drug Administration (FDA) does not treat ageing as a disease, so there is no route to approving a medicine that slows it. Would-be longevity drugs must instead win approval to treat a specific condition, often one linked to ageing, and then try to expand to others.
50|In parallel, drugmakers are looking for scientifically proven ways to add healthy years—a far more arduous process.
生词:
in parallel /ɪn ˈperəˌlel/:与此同时;另一条路线并行。
scientifically proven /ˌsaɪəˈntɪfɪkəliː ˈpruːvən/:有科学验证的。
healthy years /ˈhelθiː ˈjɪrz/:健康生活年数(健康寿命)
arduous /ˈɑːrdʒuːəs/:艰难的;费力的。
结构:
主干:drugmakers(主语)+are looking for(谓语)+scientifically proven ways(宾语)。
In parallel 是承接两条赛道的状语;to add healthy years 是不定式后置定语修饰 ways;破折号后 a far more arduous process 是对前面研发工作的总结性同位说明。
翻译:与此同时,药企正寻找经过科学验证的办法,为人们增加健康寿命——这是一项困难得多的工作。
51|America’s Food and Drug Administration (FDA) does not treat ageing as a disease, so there is no route to approving a medicine that slows it.
生词:
FDA /ˌef diː ˈeɪ/:美国食品药品监督管理局。
ageing /ageing/:衰老(随时间出现的生理变化)
approving /əˈpruːvɪŋ/:审批;批准。
medicine /ˈmedəsən/:药物。
结构:
前分句主干:America’s Food and Drug Administration(主语)+does not treat(谓语)+ageing(宾语)+as a disease(宾补)。
so 引出结果:there is no route...;route to approving a medicine 里的 to 是介词,后面必须接动名词 approving,构成“通向某种审批方式的途径”;that slows it 是定语从句修饰 medicine,it 指 ageing。
翻译:美国食品药品监督管理局不把衰老本身视为疾病,因此目前不存在直接批准‘延缓衰老药’的既定审批途径。
52|Would-be longevity drugs must instead win approval to treat a specific condition, often one linked to ageing, and then try to expand to others.
生词:
longevity /lɑːnˈdʒevəti/:长寿;寿命延长研究或服务。
drugs /ˈdrʌɡz/:药物。
win approval /ˈwɪn əˈpruːvəl/:获得监管部门批准。
specific condition /spəˈsɪfɪk kəˈndɪʃən/:具体疾病;适应证。
ageing /ageing/:衰老(随时间出现的生理变化)
expand to others /ɪkˈspænd ˈtuː ˈʌðɚz/:扩展到其他适应证。
结构:
主干:Would-be longevity drugs(主语)+must win(谓语)+approval(宾语),and then+try(并列谓语)+to expand to others(不定式宾语)。
to treat a specific condition 修饰 approval,说明审批针对何种适应证;often one linked to ageing 是插入的同位语,one 指 condition,linked to ageing 为过去分词定语;others 指其他疾病/适应证。
翻译:有志于成为长寿药物的产品,必须先获批治疗某种特定疾病——通常是与衰老相关的疾病——再尝试扩展适应证。
第十二段|GLP-1药物与生物年龄时钟
本段原文|GLP-1s show how that might work. First approved for diabetes and then obesity, these drugs have since been shown to help with heart disease, sleep apnoea and kidney problems, all of which become more common with age. By lowering the risk of such conditions, the drugs may thus help people live longer. At a conference last month Lilly and Novo, its Danish rival, presented data suggesting that patients taking their GLP-1s were ageing more slowly. The yardstick was “ageing clocks”, which estimate how old a body really is (as opposed to how many birthdays it has had) from chemical marks on DNA or the mix of proteins in the blood. Novo found the biological age of the hearts of patients on its GLP-1s to be up to four years younger compared with those on a placebo, though all were overweight or diabetic. Lilly calls its own results preliminary.
53|GLP-1s show how that might work.
生词:
GLP-1s /ˌdʒiː el ˌpiː ˈwʌnz/:GLP-1类药物(胰高血糖素样肽-1相关药物;部分具有明确治疗适应证)
might /ˈmaɪt/:原文实词;结合语境识别具体意义。
结构:
主干:GLP-1s(主语)+show(谓语)+how that might work(宾语从句);how 表方式,that 指‘先以具体疾病获批、再扩展适应证’的策略。
翻译:GLP-1类药物展示了这条路径可能怎样运作。
54|First approved for diabetes and then obesity, these drugs have since been shown to help with heart disease, sleep apnoea and kidney problems, all of which become more common with age.
生词:
first /ˈfɝst/:首先;第一步。
obesity /oʊˈbiːsətiː/:肥胖症。
drugs /ˈdrʌɡz/:药物。
heart disease /ˈhɑːrt dɪˈziːz/:心脏疾病。
sleep apnoea /ˈsliːp apnoea/:睡眠呼吸暂停(睡眠时呼吸反复中断)
kidney problems /ˈkɪdniː ˈprɑːbləmz/:肾脏问题。
结构:
主干:these drugs(主语)+have been shown(现在完成时被动谓语)+to help with heart disease, sleep apnoea and kidney problems(不定式补足)。
First approved for diabetes and then obesity 是过去分词状语,说明先后批准的适应证;all of which become more common with age 为非限制性定语从句,which 指三类疾病,all of which(主语)+become(系动词)+more common(表语)。
注意‘可帮助治疗某些疾病’与‘已经证实延长健康人寿命’不是同一研究结论。
翻译:这些药物先获批用于糖尿病,后来用于肥胖症,如今又被证明可帮助治疗心脏病、睡眠呼吸暂停和肾脏问题,而这些疾病会随年龄增长更加常见。
55|By lowering the risk of such conditions, the drugs may thus help people live longer.
生词:
lowering the risk /ˈloʊɚɪŋ ðə ˈrɪsk/:降低风险。
conditions /kəˈndɪʃənz/:疾病状况;特定病症。
drugs /ˈdrʌɡz/:药物。
结构:
主干:the drugs(主语)+may help(谓语)+people(宾语)+live longer(省to不定式宾补)。
By lowering the risk of such conditions 是 by + 动名词的方式/原因状语;thus 标记推断,may 表不确定性,属于从降低风险推到可能延寿的合理猜测。
翻译:通过降低这些疾病的风险,相关药物因此可能帮助部分人群活得更久。
56|At a conference last month Lilly and Novo, its Danish rival, presented data suggesting that patients taking their GLP-1s were ageing more slowly.
生词:
Lilly /ˈlɪli/:礼来(制药企业)
presented data /priːˈzentɪd ˈdeɪtə/:展示数据;研究结果。
suggesting /səˈdʒestɪŋ/:暗示;提示研究结果可能表明。
their /ˈðer/:他们的;其。
GLP-1s /ˌdʒiː el ˌpiː ˈwʌnz/:GLP-1类药物(胰高血糖素样肽-1相关药物;部分具有明确治疗适应证)
ageing /ageing/:衰老(随时间出现的生理变化)
结构:
主干:Lilly and Novo(主语)+presented(谓语)+data(宾语);At a conference last month 为时间地点状语。
its Danish rival 是 Novo 的同位语;suggesting that... 为现在分词后置定语修饰 data;that 从句内部:patients taking their GLP-1s(主语,taking...为定语)+were ageing(谓语)+more slowly(状语)。
翻译:在上个月的一次会议上,礼来和丹麦竞争对手诺和诺德展示了数据,提示使用其GLP-1类药物的患者可能衰老得更慢。
57|The yardstick was “ageing clocks”, which estimate how old a body really is (as opposed to how many birthdays it has had) from chemical marks on DNA or the mix of proteins in the blood.
生词:
yardstick /ˈjɑːrdˌstɪk/:衡量尺度;衡量标准。
ageing clocks /ˈeɪdʒɪŋ klɑːks/:衰老时钟(根据生物标志物估算生物年龄的算法)
chemical marks /ˈkeməkəl ˈmɑːrks/:化学标记。
DNA /ˌdiː en ˈeɪ/:脱氧核糖核酸(遗传物质)
proteins /ˈproʊˌtiːnz/:蛋白质。
结构:
主干:The yardstick(主语)+was(系动词)+ageing clocks(表语)。
which estimate how old a body really is... 为非限制性定语从句修饰 clocks,内部 which(主语)+estimate(谓语)+how old a body really is(宾语从句)。
宾语从句中 a body(主语)+is(系动词)+how old(表语);as opposed to how many birthdays it has had 是对比插入语;from chemical marks on DNA or the mix of proteins in the blood 是检测依据的介词短语。
翻译:衡量工具是‘衰老时钟’:它通过DNA上的化学标记或血液蛋白质组合,估算身体的生物年龄,而非仅看过了多少个生日。
58|Novo found the biological age of the hearts of patients on its GLP-1s to be up to four years younger compared with those on a placebo, though all were overweight or diabetic.
生词:
biological age /ˌbaɪəˈlɑːdʒɪkəl eɪdʒ/:生物年龄(据生理指标估计的年龄状态)
GLP-1s /ˌdʒiː el ˌpiː ˈwʌnz/:GLP-1类药物(胰高血糖素样肽-1相关药物;部分具有明确治疗适应证)
years /ˈjɪrz/:年;年数。
placebo /pləˈsiːboʊ/:安慰剂(无对应有效药物成分的对照处理)
结构:
主干:Novo(主语)+found(谓语)+the biological age of the hearts...(宾语)+to be up to four years younger(宾语补足语);属于 find + 宾语 + to be... 结构。
of patients on its GLP-1s 是 age/hearts 的限定;compared with those on a placebo 是对比状语,those 指安慰剂组患者的对应指标;though all were overweight or diabetic 是让步从句,限定样本而非一般健康人。
翻译:诺和诺德发现,与安慰剂组相比,服用其GLP-1类药物患者的心脏生物年龄指标最多年轻约四岁,不过受试者均患肥胖症或糖尿病。
59|Lilly calls its own results preliminary.
生词:
Lilly /ˈlɪli/:礼来(制药企业)
preliminary /prɪˈlɪməˌneriː/:初步的;尚待确认的。
calls /ˈkɔːlz/:原文实词;结合语境识别具体意义。
结构:
主干:Lilly(主语)+calls(谓语)+its own results(宾语)+preliminary(宾补);call + 宾语 + 形容词 表‘认为/称某结果如何’。
翻译:礼来则称自己的研究结果仍属初步阶段。
第十三段|从罕见病到大众市场
网络图片 13|全球寿命与健康寿命变化图(WIPO)。WIPO《全球创新指数》中的预期寿命与健康寿命趋势数据,可用于解释长寿技术为什么形成大众市场。
本段原文|Whatever GLP-1s turn out to do for ageing, they have already changed how big pharma thinks about the opportunity. Five or ten years ago drugmakers were chasing rare diseases, says Stephen Roper of L.E.K., a consultancy. But GLP-1s have re-established the appeal of mass-market drugs.
60|Whatever GLP-1s turn out to do for ageing, they have already changed how big pharma thinks about the opportunity.
生词:
GLP-1s /ˌdʒiː el ˌpiː ˈwʌnz/:GLP-1类药物(胰高血糖素样肽-1相关药物;部分具有明确治疗适应证)
ageing /ageing/:衰老(随时间出现的生理变化)
big pharma /ˈbɪɡ ˈfɑːrmə/:大型制药企业。
结构:
主干:they(主语,指GLP-1s)+have changed(谓语)+how big pharma thinks about the opportunity(宾语从句)。
Whatever GLP-1s turn out to do for ageing 为让步状语从句,Whatever 表‘无论最终怎样’;how big pharma thinks... 为宾语从句,内部主语 big pharma、谓语 thinks、about the opportunity 为介词宾语;现在完成时强调商业观念已经改变。
翻译:无论GLP-1类药物最终对衰老有何作用,它们已改变大型药企看待长寿机会的方式。
61|Five or ten years ago drugmakers were chasing rare diseases, says Stephen Roper of L.E.K., a consultancy.
生词:
years /ˈjɪrz/:年;年数。
rare diseases /ˈrer dɪˈziːzəz/:罕见疾病。
L.E.K. /ˌel iː ˈkeɪ/:战略咨询企业名称。
结构:
引语主干:drugmakers(主语)+were chasing(过去进行时谓语)+rare diseases(宾语);Five or ten years ago 为时间状语。
says Stephen Roper of L.E.K. 是后置报道语;a consultancy 是 L.E.K. 的同位语;过去进行时突出当时持续的行业偏好。
翻译:咨询公司L.E.K.的斯蒂芬·罗珀说,五到十年前药企还主要追逐罕见病市场。
62|But GLP-1s have re-established the appeal of mass-market drugs.
生词:
GLP-1s /ˌdʒiː el ˌpiː ˈwʌnz/:GLP-1类药物(胰高血糖素样肽-1相关药物;部分具有明确治疗适应证)
re-established /ˈreɪ ɪˈstæblɪʃt/:重新确立。
mass-market drugs /ˈmæs ˈmɑːrkət ˈdrʌɡz/:大众市场药物(潜在适用人群广泛)
结构:
主干:GLP-1s(主语)+have re-established(现在完成时谓语)+the appeal of mass-market drugs(宾语);But 对比前句罕见病策略。
翻译:但GLP-1类药物重新证明了大众市场药品的吸引力。
第十四段|药企合作与资本押注
本段原文|Rather than develop longevity treatments themselves, pharma giants mostly buy options on biotechs’ work. Lilly has struck a deal with Insilico worth up to $2.75bn. Novartis, a Swiss drugmaker, has one worth up to $550m with BioAge Labs, another biotech. The ranks of such startups are growing. Last year longevity biotechs raised $18.4bn, more than in the previous ten years combined (see chart).
63|Rather than develop longevity treatments themselves, pharma giants mostly buy options on biotechs’ work.
生词:
longevity /lɑːnˈdʒevəti/:长寿;寿命延长研究或服务。
treatments /ˈtriːtmənts/:治疗项目;干预措施。
pharma giants /ˈfɑːrmə ˈdʒaɪənts/:大型制药企业。
options on biotechs’ work /ˈɑːpʃənz ˈɑːn ˈbaɪoʊˌteks ˈwɝk/:对生物科技研发项目的选择权或合作权益。
结构:
主干:pharma giants(主语)+mostly buy(谓语)+options on biotechs’ work(宾语)。
Rather than develop longevity treatments themselves 是 rather than + 省略to的不定式对照结构,表示‘不是自己研发,而是购买相关权益’;options 在此为商业合作/许可选择权,不等同于已经买断全部技术。
翻译:制药巨头通常不自行开发长寿疗法,而是购买生物科技公司项目的选择权。
64|Lilly has struck a deal with Insilico worth up to $2.75bn.
生词:
Lilly /ˈlɪli/:礼来(制药企业)
struck a deal /sˈtrʌk ə ˈdiːl/:达成协议。
worth up to /ˈwɝθ ˈʌp ˈtuː/:最高价值可达(不等于已支付)
结构:
主干:Lilly(主语)+has struck(现在完成时谓语)+a deal(宾语)+with Insilico(合作对象);worth up to $2.75bn 为形容词短语后置修饰 deal,up to 表金额上限,并非已经支付总额。
翻译:礼来与英矽智能达成了一项最高价值27.5亿美元的合作协议。
65|Novartis, a Swiss drugmaker, has one worth up to $550m with BioAge Labs, another biotech.
生词:
Novartis /noʊˈvɑːrtɪs/:诺华(瑞士制药企业)
worth up to /ˈwɝθ ˈʌp ˈtuː/:最高价值可达(不等于已支付)
Swiss /ˈswɪs/:原文实词;结合语境识别具体意义。
结构:
主干:Novartis(主语)+has(谓语)+one(宾语,指 deal)+with BioAge Labs(合作对象)。
a Swiss drugmaker 是 Novartis 同位语;worth up to $550m 为后置修饰 one;another biotech 为 BioAge Labs 同位语。
翻译:瑞士药企诺华也与另一家生物科技公司BioAge Labs有一项最高价值5.5亿美元的协议。
66|The ranks of such startups are growing.
生词:
startups /ˈstɑːˌrtʌps/:初创公司。
growing /ˈɡroʊɪŋ/:不断增加;壮大。
ranks /ˈræŋks/:原文实词;结合语境识别具体意义。
结构:
主干:The ranks of such startups(主语)+are growing(现在进行时谓语);ranks 在此表示群体规模,不是排名。
翻译:这类初创企业的数量正在增加。
67|Last year longevity biotechs raised $18.4bn, more than in the previous ten years combined (see chart).
生词:
longevity /lɑːnˈdʒevəti/:长寿;寿命延长研究或服务。
biotechs /ˈbaɪoʊˌteks/:生物科技企业。
years /ˈjɪrz/:年;年数。
combined /kəˈmbaɪnd/:合计;累计。
结构:
主干:longevity biotechs(主语)+raised(谓语)+$18.4bn(宾语);Last year 为时间状语。
more than in the previous ten years combined 是比较结构,省略了 raised,比较去年与前十年融资规模;see chart 提醒读者结合原文图表审视数据。
翻译:去年,长寿生物科技公司共筹集184亿美元,超过此前十年筹资总额之和。
第十五段|双重目的疗法与肺纤维化
本段原文|Insilico calls its products “dual-purpose therapeutics”, each targeting ageing and a specific disease at the same time. A drug aimed only at ageing, argues Dr Zhavoronkov, its boss, would struggle to attract serious investors. Insilico’s most advanced candidate, rentosertib, treats idiopathic pulmonary fibrosis, a disease that scars the lungs. It entered a late-stage trial in July, making it one of the furthest along of any drug designed with ageing in mind. In an earlier trial of 42 patients, ageing clocks suggested that those on the drug were biologically younger than those on a placebo, by around three years on some measures, though all were already ill.
68|Insilico calls its products “dual-purpose therapeutics”, each targeting ageing and a specific disease at the same time.
生词:
dual-purpose therapeutics /ˈduːəl ˈpɝpəs ˌθerəˈpjuːtɪks/:双重目的疗法(同时面向具体疾病和衰老相关机制)
targeting /ˈtɑːrɡətɪŋ/:以……为靶点或目标。
ageing /ageing/:衰老(随时间出现的生理变化)
结构:
主干:Insilico(主语)+calls(谓语)+its products(宾语)+dual-purpose therapeutics(宾补)。
each targeting ageing and a specific disease at the same time 是独立主格/补充性非谓语结构,each 指每款产品,targeting 为现在分词,说明‘双重目的’具体是什么。
翻译:英矽智能把自家产品称为‘双重用途疗法’,每个产品同时瞄准衰老与一种具体疾病。
69|A drug aimed only at ageing, argues Dr Zhavoronkov, its boss, would struggle to attract serious investors.
生词:
aimed /ˈeɪmd/:以……为目标的。
ageing /ageing/:衰老(随时间出现的生理变化)
serious investors /ˈsɪriːəs ˌɪˈnvestɚz/:专业投资者;认真投入的投资人。
结构:
主干:A drug aimed only at ageing(主语)+would struggle(谓语)+to attract serious investors(不定式补足语)。
aimed only at ageing 是过去分词后置定语;argues Dr Zhavoronkov 是插入的报道语;its boss 是人物同位语;would 表假设判断,不是针对具体上市药品的事实。
翻译:公司负责人扎沃龙科夫认为,只针对衰老的药物很难吸引严肃投资者。
70|Insilico’s most advanced candidate, rentosertib, treats idiopathic pulmonary fibrosis, a disease that scars the lungs.
生词:
candidate /ˈkændədeɪt/:候选药物(尚未证明获批)
rentosertib /ˌren.toʊˈsɝː.tɪb/:rentosertib(药物候选物名称)
idiopathic pulmonary fibrosis /ˌɪdiəˈpæθɪk ˈpʊlməneri faɪˈbroʊsɪs/:特发性肺纤维化(肺组织持续形成瘢痕的疾病)
scars /ˈskɑːrz/:使结疤;导致纤维化。
结构:
主干:Insilico’s most advanced candidate, rentosertib(主语及同位语)+treats(谓语,报道所指研发用途)+idiopathic pulmonary fibrosis(宾语)。
a disease that scars the lungs 为疾病名同位语;that scars the lungs 是定语从句,that(主语)+scars(谓语)+the lungs(宾语);candidate 一词提醒其仍属研发阶段,不等同于已获批。
翻译:英矽智能进展最快的候选药物rentosertib用于研究治疗特发性肺纤维化,即一种使肺组织结疤的疾病。
71|It entered a late-stage trial in July, making it one of the furthest along of any drug designed with ageing in mind.
生词:
entered /ˈentɚd/:进入;开始参加。
late-stage trial /ˈleɪt ˈsteɪdʒ ˈtraɪəl/:后期临床试验。
ageing /ageing/:衰老(随时间出现的生理变化)
结构:
主干:It(主语,指 rentosertib)+entered(谓语)+a late-stage trial(宾语)+in July(时间状语)。
making it one of the furthest along... 为现在分词结果状语,表示进入后期试验后的地位;designed with ageing in mind 是过去分词定语修饰 drug,限定比较对象。
翻译:该药于7月进入后期临床试验,成为以衰老为研发考量的候选药物中进展较快者之一。
72|In an earlier trial of 42 patients, ageing clocks suggested that those on the drug were biologically younger than those on a placebo, by around three years on some measures, though all were already ill.
生词:
ageing clocks /ˈeɪdʒɪŋ klɑːks/:衰老时钟(根据生物标志物估算生物年龄的算法)
suggested /səˈdʒestɪd/:提出;暗示(并非已证实)
biologically younger /baɪəˈlɑːdʒɪkliː ˈjʌŋɡɚ/:生物年龄估计更年轻。
placebo /pləˈsiːboʊ/:安慰剂(无对应有效药物成分的对照处理)
years /ˈjɪrz/:年;年数。
on some measures /ˈɑːn ˈsʌm ˈmeʒɚz/:在部分指标上。
all were already ill /ˈɔːl ˈwɝ ɔːˈlrediː ˈɪl/:所有受试者原本都已患病。
结构:
主干:ageing clocks(主语)+suggested(谓语)+that...(宾语从句);In an earlier trial of 42 patients 是背景状语。
that 从句内部:those on the drug(主语,those 指患者)+were(系动词)+biologically younger(表语)+than those on a placebo(比较对象);by around three years on some measures 限定‘约三岁’仅见于部分指标。
though all were already ill 为让步状语从句,强调样本不是健康人;时钟分数变化不自动意味着寿命真实延长。
翻译:在此前一项42名患者的试验中,衰老时钟指标显示,部分指标上用药组的生物年龄估计值较安慰剂组年轻约三岁,但所有受试者原本都患病。
第十六段|表观遗传重编程的未来想象
本段原文|Other startups are looking to reverse ageing altogether. They include Mr Altman’s Retro; Altos Labs; and NewLimit, co-founded by Brian Armstrong, a crypto entrepreneur, which in June announced $435m in fresh funding. Most are betting on “epigenetic reprogramming”, the idea that the chemical switches on DNA, which become muddled with age, can be reset.
73|Other startups are looking to reverse ageing altogether.
生词:
startups /ˈstɑːˌrtʌps/:初创公司。
reverse ageing /rɪˈvɝs ageing/:逆转衰老(目前仍是研究目标)
altogether /ˌɔːltəˈɡeðɚ/:彻底地;完全地。
结构:
主干:Other startups(主语)+are looking(谓语)+to reverse ageing altogether(不定式补足语);altogether 强化‘完全逆转’的宏大目标。
翻译:另一些初创企业则尝试彻底逆转衰老。
74|They include Mr Altman’s Retro; Altos Labs; and NewLimit, co-founded by Brian Armstrong, a crypto entrepreneur, which in June announced $435m in fresh funding.
生词:
co-founded /ˈkoʊ ˈfaʊndɪd/:共同创办。
crypto entrepreneur /ˈkrɪptoʊ ˌɑːntrəprəˈnɝ/:加密货币行业创业者。
fresh funding /ˈfreʃ ˈfʌndɪŋ/:新一轮融资。
结构:
主干:They(主语)+include(谓语)+Retro, Altos Labs and NewLimit(并列宾语)。
co-founded by Brian Armstrong 为过去分词后置定语,修饰 NewLimit;a crypto entrepreneur 为 Armstrong 同位语;which in June announced $435m... 为非限制性定语从句,指 NewLimit,which(主语)+announced(谓语)+$435m in fresh funding(宾语)。
翻译:它们包括奥尔特曼的Retro、Altos Labs以及由加密货币创业者布莱恩·阿姆斯特朗共同创立的NewLimit;后者于6月宣布获得4.35亿美元新资金。
75|Most are betting on “epigenetic reprogramming”, the idea that the chemical switches on DNA, which become muddled with age, can be reset.
生词:
epigenetic reprogramming /ˌepɪdʒəˈnetɪk ˌriːˈproʊɡræmɪŋ/:表观遗传重编程(尝试重置影响基因表达的调控状态)
chemical switches /ˈkeməkəl ˈswɪtʃəz/:化学调控开关(比喻影响基因表达的表观修饰)
DNA /ˌdiː en ˈeɪ/:脱氧核糖核酸(遗传物质)
muddled /ˈmʌdəld/:变得混乱的。
reset /riːˈset/:重置;重新设定。
结构:
主干:Most(主语,指多数初创企业)+are betting on(谓语)+epigenetic reprogramming(宾语)。
the idea that... 为同位解释,说明该技术设想;that 之后为同位语从句:the chemical switches on DNA(主语)+can be reset(被动谓语);which become muddled with age 为插入的非限制性定语从句修饰 switches。
这里是技术假说与研发目标,不代表在人类中已可安全实现全身返老还童。
翻译:多数企业押注‘表观遗传重编程’,即希望重置随着年龄增长而紊乱的DNA化学调控开关。
第十七段|过去的教训:高期望与失败
本段原文|Previous efforts by drugmakers to create longevity treatments have ended in disappointment. In 2008 Britain’s GSK bought Sirtris, a biotech developing drugs inspired by resveratrol, a compound in red wine. Five years later it shut the firm down. Calico, launched by Google in 2013 to tackle ageing, has achieved little. Unity Biotechnology, a startup focused on clearing out ageing cells, laid off its entire staff in May last year after disappointing trials.
76|Previous efforts by drugmakers to create longevity treatments have ended in disappointment.
生词:
previous efforts /ˈpriːviːəs ˈefɚts/:此前尝试。
longevity /lɑːnˈdʒevəti/:长寿;寿命延长研究或服务。
treatments /ˈtriːtmənts/:治疗项目;干预措施。
ended in disappointment /ˈendəd ɪn ˌdɪsəˈpɔɪntmənt/:以失望告终。
结构:
主干:Previous efforts by drugmakers(主语)+have ended(现在完成时谓语)+in disappointment(结果状语)。
to create longevity treatments 为不定式后置定语,说明 efforts 的目标;句子为后文失败案例作总起。
翻译:药企过去开发长寿治疗的尝试,曾多次以失望告终。
77|In 2008 Britain’s GSK bought Sirtris, a biotech developing drugs inspired by resveratrol, a compound in red wine.
生词:
Britain /ˈbrɪtən/:英国。
drugs /ˈdrʌɡz/:药物。
resveratrol /rɛzˈverətrɔːl/:白藜芦醇(植物中存在的一种多酚化合物)
compound /ˈkɑːmpaʊnd/:化合物。
结构:
主干:Britain’s GSK(主语)+bought(谓语)+Sirtris(宾语);In 2008 是时间状语。
a biotech developing drugs... 是 Sirtris 的同位语;developing... 为现在分词修饰 biotech;inspired by resveratrol 为过去分词修饰 drugs;a compound in red wine 是 resveratrol 同位语。
翻译:2008年,英国药企葛兰素史克收购了Sirtris,这家生物科技公司开发以红葡萄酒中白藜芦醇为灵感的药物。
78|Five years later it shut the firm down.
生词:
years /ˈjɪrz/:年;年数。
later /ˈleɪtɚ/:稍后;后来。
结构:
主干:it(主语,指GSK)+shut down(谓语短语)+the firm(宾语,指Sirtris);Five years later 是时间状语。
翻译:五年后,GSK关闭了这家公司。
79|Calico, launched by Google in 2013 to tackle ageing, has achieved little.
生词:
Calico /ˈkælɪkoʊ/:Calico(衰老研究企业)
launched /ˈlɔːntʃt/:创立;推出。
ageing /ageing/:衰老(随时间出现的生理变化)
结构:
主干:Calico(主语)+has achieved(现在完成时谓语)+little(宾语,表示成果有限)。
launched by Google in 2013 为过去分词定语修饰 Calico;to tackle ageing 是目的不定式,说明公司创办目的。
翻译:谷歌2013年创立的Calico旨在研究衰老,但迄今成果有限。
80|Unity Biotechnology, a startup focused on clearing out ageing cells, laid off its entire staff in May last year after disappointing trials.
生词:
startup /ˈstɑːˌrtʌp/:初创企业。
clearing out ageing cells /ˈklɪrɪŋ ˈaʊt ageing ˈselz/:清除衰老细胞(衰老细胞清除研究方向)
laid off /ˈleɪd ˈɔːf/:裁员;解雇。
entire staff /ɪˈntaɪɚ ˈstæf/:全部员工。
disappointing trials /ˌdɪsəˈpɔɪntɪŋ ˈtraɪəlz/:结果不理想的试验。
结构:
主干:Unity Biotechnology(主语)+laid off(谓语)+its entire staff(宾语)+in May last year(时间状语)。
a startup focused on clearing out ageing cells 是主语同位语,focused on... 为过去分词修饰 startup;after disappointing trials 为原因/时间状语,说明裁员背景。
翻译:专注清除衰老细胞的Unity Biotechnology在试验结果令人失望后,于去年5月裁撤了全部员工。
第十八段|结尾:等待证据的人与寻找永生的人
网络图片 18|新型长寿研发企业的研究与实验场景。Retro 官方图片可呈现初创企业的研究现场,与报道结尾“等待人体试验验证”对应。
本段原文|The new wave of biotech founders and investors argue this time will be different, thanks in part to AI, which they hope will accelerate discoveries. The first human trials for a drug targeting epigenetic reprogramming—a liver treatment developed by NewLimit—may begin next year. While the results are gathered, consumers will keep seeking immortality elsewhere.
81|The new wave of biotech founders and investors argue this time will be different, thanks in part to AI, which they hope will accelerate discoveries.
生词:
will be /ˈwɪl ˈbiː/:将会是;将处于某种状态。
different /ˈdɪfɚənt/:不同的;有差异的。
thanks in part to /ˈθæŋks ɪn ˈpɑːrt ˈtuː/:部分归因于。
AI /ˈaɪ/:人工智能。
accelerate discoveries /æˈkselɚˌeɪt dɪˈskʌvɚiːz/:加速新发现。
结构:
主干:The new wave of biotech founders and investors(主语)+argue(谓语)+[this time will be different](宾语从句,省略that)。
thanks in part to AI 为原因状语;which they hope will accelerate discoveries 为非限制性定语从句修饰 AI,内部 they hope 为插入性认知表述,核心为 AI(主语)+will accelerate(谓语)+discoveries(宾语);hope 表预测不确定性。
翻译:新一波生物科技创始人与投资者认为,这次的结果会不同,部分原因是他们希望AI能加速新发现。
82|The first human trials for a drug targeting epigenetic reprogramming—a liver treatment developed by NewLimit—may begin next year.
生词:
first human trials /ˈfɝst ˈhjuːmən ˈtraɪəlz/:首次人体临床试验。
targeting /ˈtɑːrɡətɪŋ/:以……为靶点或目标。
epigenetic reprogramming /ˌepɪdʒəˈnetɪk ˌriːˈproʊɡræmɪŋ/:表观遗传重编程(尝试重置影响基因表达的调控状态)
may begin /ˈmeɪ bɪˈɡɪn/:可能开始(尚未发生)
结构:
主干:The first human trials(主语)+may begin(谓语)+next year(时间状语);may 表预计而非已开始。
for a drug targeting epigenetic reprogramming 修饰 trials,说明临床试验针对的产品;targeting... 为现在分词后置定语修饰 drug;破折号中 a liver treatment developed by NewLimit 是 drug 的同位解释,developed by... 是过去分词定语。
翻译:NewLimit开发的一种肝脏治疗药物据称针对表观遗传重编程,其首批人体试验可能在明年开始。
83|While the results are gathered, consumers will keep seeking immortality elsewhere.
生词:
while the results are gathered /ˈwaɪl ðə rɪˈzʌlts ˈɑːr ˈɡæðɚd/:在试验数据收集期间。
immortality /ˌɪmɔːrˈtæləti/:永生;不朽(本文是长期商业追求,并非现实技术)
elsewhere /ˈelˌswer/:在别处;通过其他渠道。
结构:
主干:consumers(主语)+will keep seeking(谓语)+immortality(宾语)+elsewhere(地点状语)。
While the results are gathered 为时间状语从句,使用被动语态 results(主语)+are gathered(谓语),表示‘在数据收集期间’;结尾呼应文章开头的消费者市场。
翻译:在等待研究结果出炉的同时,消费者仍将继续到其他地方寻找‘永生’的希望。
07|重点词汇总结(含音标)
重点单词/短语
IPA音标
原文语境义
longevity
/lɑːnˈdʒevəti/
长寿;寿命延长研究或服务
immortality
/ˌɪmɔːrˈtæləti/
永生;不朽(本文是长期商业追求,并非现实技术)
cryotherapy
/ˌkraɪoʊˈθerəpi/
冷冻疗法(利用低温的干预方式;不能直接等同于延寿)
hyperbaric chamber
/ˌhaɪpərˈbærɪk ˈtʃeɪmbər/
高压氧舱(在高于普通气压的环境中供氧的设备)
intravenous drips
/ˌɪntrəˈviːnəs drɪps/
静脉滴注
NAD+
/ˌen eɪ ˈdiː plʌs/
烟酰胺腺嘌呤二核苷酸;参与细胞能量代谢的辅酶
lifespan
/ˈlaɪfˌspæn/
寿命长度
chronic disease
/ˈkrɑːnɪk dɪˈziːz/
慢性疾病(长期存在、需管理的健康问题)
OECD
/ˌoʊ iː siː ˈdiː/
经济合作与发展组织(主要由高收入经济体组成)
evangelists
/ɪˈvændʒəlɪsts/
热情倡导者;积极推广者
dubious efficacy
/ˈduːbiːəs ˈefɪˌkæsiː/
疗效存疑(尚缺可靠证据)
biotechs
/ˈbaɪoʊˌteks/
生物科技企业
obesity
/oʊˈbiːsətiː/
肥胖症
GLP-1s
/ˌdʒiː el ˌpiː ˈwʌnz/
GLP-1类药物(胰高血糖素样肽-1相关药物;部分具有明确治疗适应证)
conventional health care
/kəˈnvenʃənəl ˈhelθ ˈker/
常规医疗照护体系
genome sequencing
/ˈdʒiːnoʊm ˈsiːkwənsɪŋ/
基因组测序(分析遗传物质的序列)
full-body scans
/ˈfʊl ˈbɑːdiː ˈskænz/
全身扫描(非特定疾病筛查手段)
MRI scan
/ˌem ɑːr ˈaɪ skæn/
磁共振成像扫描(利用磁场与射频成像)
experimental treatments
/ɪkˌsperɪˈmentəl ˈtriːtmənts/
实验性治疗(安全有效性尚未完全确认)
gene therapy
/ˈdʒiːn ˈθerəpiː/
基因治疗(通过改变遗传物质治疗特定疾病的方式)
stem-cell infusions
/ˈstem ˈsel ˌɪnˈfjuːʒənz/
干细胞输注
injectable peptides
/ˌɪˈndʒektəbəl ˈpeˌptaɪdz/
可注射肽类产品(肽是氨基酸短链)
American College of Radiology
/əˈmerəkən ˈkɑːlɪdʒ ˈʌv ˌreɪdiːˈɑːlədʒiː/
美国放射学会(影像医学专业学术组织)
over-diagnosis
/ˈoʊvɚ ˌdaɪəˈɡnoʊsəs/
过度诊断(发现不会危害健康的异常并导致过度干预)
inconclusive
/ˌɪnkənˈkluːsɪv/
结论不明确的;尚不能确认的
scientifically proven
/ˌsaɪəˈntɪfɪkəliː ˈpruːvən/
有科学验证的
FDA
/ˌef diː ˈeɪ/
美国食品药品监督管理局
win approval
/ˈwɪn əˈpruːvəl/
获得监管部门批准
sleep apnoea
/ˈsliːp apnoea/
睡眠呼吸暂停(睡眠时呼吸反复中断)
ageing clocks
/ˈeɪdʒɪŋ klɑːks/
衰老时钟(根据生物标志物估算生物年龄的算法)
biological age
/ˌbaɪəˈlɑːdʒɪkəl eɪdʒ/
生物年龄(据生理指标估计的年龄状态)
placebo
/pləˈsiːboʊ/
安慰剂(无对应有效药物成分的对照处理)
DNA
/ˌdiː en ˈeɪ/
脱氧核糖核酸(遗传物质)
preliminary
/prɪˈlɪməˌneriː/
初步的;尚待确认的
mass-market drugs
/ˈmæs ˈmɑːrkət ˈdrʌɡz/
大众市场药物(潜在适用人群广泛)
dual-purpose therapeutics
/ˈduːəl ˈpɝpəs ˌθerəˈpjuːtɪks/
双重目的疗法(同时面向具体疾病和衰老相关机制)
idiopathic pulmonary fibrosis
/ˌɪdiəˈpæθɪk ˈpʊlməneri faɪˈbroʊsɪs/
特发性肺纤维化(肺组织持续形成瘢痕的疾病)
late-stage trial
/ˈleɪt ˈsteɪdʒ ˈtraɪəl/
后期临床试验
epigenetic reprogramming
/ˌepɪdʒəˈnetɪk ˌriːˈproʊɡræmɪŋ/
表观遗传重编程(尝试重置影响基因表达的调控状态)
resveratrol
/rɛzˈverətrɔːl/
白藜芦醇(植物中存在的一种多酚化合物)
first human trials
/ˈfɝst ˈhjuːmən ˈtraɪəlz/
首次人体临床试验
08|重点词汇例句(可迁移表达)
01|longevity /lɑːnˈdʒevəti/:长寿;寿命延长研究或服务
Longevity research should distinguish hope from clinical evidence.
翻译:长寿研究应区分希望与临床证据。
02|cryotherapy /ˌkraɪoʊˈθerəpi/:冷冻疗法(利用低温的干预方式;不能直接等同于延寿)
A refreshing feeling after cryotherapy does not prove a longer lifespan.
翻译:冷冻疗法后的清爽感并不能证明寿命得到延长。
03|NAD+ /ˌen eɪ ˈdiː plʌs/:烟酰胺腺嘌呤二核苷酸;参与细胞能量代谢的辅酶
A change in NAD+ levels does not by itself establish a clinical benefit.
翻译:NAD+水平变化本身并不能证明有临床益处。
04|dubious efficacy /ˈduːbiːəs ˈefɪˌkæsiː/:疗效存疑(尚缺可靠证据)
Consumers should be cautious about products of dubious efficacy.
翻译:消费者应谨慎对待疗效存疑的产品。
05|full-body scans /ˈfʊl ˈbɑːdiː ˈskænz/:全身扫描(非特定疾病筛查手段)
Full-body scans may detect findings that never cause symptoms.
翻译:全身扫描可能发现一些终生不会引起症状的异常。
06|over-diagnosis /ˈoʊvɚ ˌdaɪəˈɡnoʊsəs/:过度诊断(发现不会危害健康的异常并导致过度干预)
Over-diagnosis can lead to unnecessary tests and treatment.
翻译:过度诊断可能导致不必要的检查和治疗。
07|scientifically proven /ˌsaɪəˈntɪfɪkəliː ˈpruːvən/:有科学验证的
A scientifically proven benefit requires reliable human evidence.
翻译:科学验证的收益需要可靠的人体研究证据。
08|win approval /ˈwɪn əˈpruːvəl/:获得监管部门批准
A new drug must win approval for a specific medical indication.
翻译:新药必须就特定医疗适应证获得批准。
09|ageing clocks /ˈeɪdʒɪŋ klɑːks/:衰老时钟(根据生物标志物估算生物年龄的算法)
Ageing clocks estimate biological patterns rather than guaranteed years of life.
翻译:衰老时钟估算生物学模式,并不保证实际寿命年数。
10|preliminary /prɪˈlɪməˌneriː/:初步的;尚待确认的
The company described the trial findings as preliminary.
翻译:公司表示该试验发现尚属初步结果。
11|late-stage trial /ˈleɪt ˈsteɪdʒ ˈtraɪəl/:后期临床试验
A late-stage trial does not automatically mean that a drug will be approved.
翻译:进入后期临床试验不意味着药物必然获批。
12|epigenetic reprogramming /ˌepɪdʒəˈnetɪk ˌriːˈproʊɡræmɪŋ/:表观遗传重编程(尝试重置影响基因表达的调控状态)
Epigenetic reprogramming is being investigated, but long-term safety remains important.
翻译:表观遗传重编程仍在研究中,长期安全性十分重要。
09|文化拓展|把外刊背后的科学与商业逻辑讲清楚
01|长寿(longevity)与健康寿命(healthspan):多活十年和健康十年不是一回事
读“延寿产业”时,首先需要辨清三个指标。lifespan(个体寿命)表示一个人实际上活了多久;life expectancy(预期寿命)是依据某时期死亡率推算的平均生存年数;healthy life expectancy,简称 HALE(健康预期寿命),则把患病、残疾等“不完全健康的年份”折算进去,关注人能以相对健康的状态生活多少年。
世界卫生组织在指标说明中将HALE定义为“在完全健康状态下可期望生活的平均年数”,它不是某个人的体检报告,也不等于“永远不得病”。举例说,同样活到85岁,甲在70岁后长期受慢性病影响,乙在80岁前仍保持较好的身体功能,两人的寿命数字相同,健康寿命却可能不同(此例仅用于说明概念,没有代入真实人群数据)。
这正是原文中Retro Biosciences提出“add ten healthy years”的关键:目标不是让大家只在死亡年龄上加十,而是设法推迟疾病和功能下降。但企业愿景、试验中某项指标改善、实际健康生活年数增加,之间存在很长的证据链。比较产品时应追问:研究对象是谁、观察多久、是否有对照组,最后改善的是化验值、生活功能,还是住院、失能和死亡等真正重要的结局?
资料来源|WHO健康预期寿命定义:https://www.who.int/data/gho/data/indicators/indicator-details/GHO/gho-ghe-hale-healthy-life-expectancy
02|同叫“长寿产业”,为什么是两条完全不同的商业路径?
报道把市场分成两条路线。第一条是 consumer longevity(消费者长寿服务):诊所、营养补充剂、身体检测、会员订阅和网红产品,往往由消费者直接付款,销售逻辑是“现在就能体验”。第二条是 biotech/pharma(生物技术与制药研发):先提出作用机制,再经历实验室验证、动物研究、人体临床试验,最后还需在特定适应证上证明获益与风险的比例可接受。前者可以很快在市场上形成收入,后者可能多年都没有产品上市。这解释了原文那句 Into the gap has rushed a business:技术前景与真正有效药物之间的空白,被商业服务迅速填补。
需要注意:两条路线不是“任何诊所服务都无效”与“所有生物科技研发都有效”的简单对立。某些检测或治疗对于明确的医学适应证很重要,但把它们打包成“人人都该做的延寿服务”是另一回事;而实验性新药即使具有合理的分子机制,也可能在人体试验中失败。评价时应把“有科研依据的机制”“已证实的具体临床益处”“监管批准的适应证”“宣称全面延寿”分层,而不能因为一家机构有白大褂、先进机器或高价套餐就默认获得科学认证。
资料来源|FDA抗衰老医疗欺诈说明:https://www.fda.gov/drugs/medication-health-fraud/medication-health-fraud-specific-diseases-and-conditions
03|为什么“身体指标检测得越多”不一定越安全?从全身MRI看过度诊断
MRI(magnetic resonance imaging,磁共振成像)是医学中重要的诊断工具,但其价值取决于使用场景。对有明确症状、家族风险或特定疾病高风险的人,医生可能有充分理由安排影像检查;对没有症状和明确危险因素的人群,常规全身筛查的收益与风险就需要单独研究。
美国放射学会(ACR)2023年声明明确指出,目前缺乏足够证据建议无症状、无相关风险者接受常规全身MRI筛查,也没有可靠证据证明此类筛查具有成本效益或能够延长生命。这里必须区分 false positive(假阳性:检测提示异常,实际并无所担忧的疾病)与 overdiagnosis(过度诊断:发现了真实存在却一生不会造成伤害的异常)。两者都可能带来焦虑和追加检查,但概念并不相同。
例如,一次全身扫描发现一个很小的偶发结节。它也许需要医学评估,但“扫描发现结节”不自动等于“提前发现致命疾病”。随后可能出现复查、活检甚至不必要的治疗,从而产生额外成本、痛苦和风险。与“查出多少异常”相比,更关键的是筛查是否通过高质量研究,降低相关疾病死亡率、改善生活质量,以及收益是否超过潜在伤害。原文所说“检测越多、可能越过度诊断”,不是否认医学影像,而是提醒:检测必须有清楚的适应证和后续处理方案。
资料来源|美国放射学会2023年声明:https://www.acr.org/News-and-Publications/Media-Center/2023/ACR-Statement-on-Screening-Total-Body-MRI
资料来源|2026年全身MRI综述:https://pmc.ncbi.nlm.nih.gov/articles/PMC13008331/
04|NAD+、低温舱、高压氧舱:生理机制不等于“已证实抗衰老”
NAD+(烟酰胺腺嘌呤二核苷酸)是细胞能量代谢的重要辅酶,参与氧化还原反应;正因为它在生物体内不可或缺,很多产品会把“提高NAD+水平”描述为“让细胞年轻”。
但这个推断至少跨越三步:第一,某种产品能否安全有效地改变人体特定组织中的NAD+水平;第二,这种变化是否改善与疾病相关的生理功能;第三,能否在长期随机对照试验中证明降低发病、失能或死亡风险。2025年《Nature Metabolism》综述认为,人体NAD+前体补充研究的临床效果仍有限,不能简单从啮齿动物研究外推到人。2026年的系统综述也指出,针对抗衰老或健康管理目的的静脉NAD+治疗缺少合格的临床结局试验。
低温舱(cryotherapy)使人在短时间内暴露于极低温,高压氧舱(hyperbaric oxygen therapy)则在加压环境中供氧。两者可能让部分体验者主观感觉精力变好,但“感觉焕发活力”与“已证明延长寿命”是两种证据层级。更重要的是,高压氧设备并非没有风险;FDA于2025年提醒医疗机构必须严格遵循操作与消防安全规范。对使用者来说,优先要关注的是“适用什么明确问题、有什么人体证据、有哪些风险、是否由合格医疗人员评估”。
资料来源|NAD+人体证据综述:https://pubmed.ncbi.nlm.nih.gov/41083806/
资料来源|2026 NAD+系统综述:https://pubmed.ncbi.nlm.nih.gov/41655607/
资料来源|FDA高压氧设备安全提示(2025-08-25):https://www.fda.gov/medical-devices/letters-health-care-providers/follow-instructions-safe-use-hyperbaric-oxygen-therapy-devices-letter-health-care-providers
05|GLP-1类药物为什么可能影响“健康寿命”,却不能直接说是“长生药”?
GLP-1(glucagon-like peptide-1,胰高血糖素样肽-1)是一种参与调控血糖与食欲的肠道激素。某些GLP-1受体激动剂已在特定人群中通过临床研究证明对糖尿病、体重管理以及部分心血管结局有益。例如,美国FDA在2024年批准司美格鲁肽用于降低符合条件的心血管疾病合并超重/肥胖成人发生重大心血管事件的风险;2024年又批准替尔泊肽用于治疗符合条件的肥胖成人中重度阻塞性睡眠呼吸暂停。它们属于不同产品和具体适应证,不能把某一种药的全部证据自动套用到整个药物类别。
原文提出一种颇有吸引力的推论:若药物能降低随年龄增长而更常见的疾病风险,或许可以改善健康寿命。但这距离“任何健康人服用后都能延寿”仍差得很远。还需研究年龄、疾病状态、用药剂量、停药后变化、长期不良反应和死亡率。
FDA在2026年11月对GLP-1受体激动剂提出了关于罕见但严重视神经病变风险的新增标签警示,进一步提醒读者,药物收益与风险必须在具体临床人群中判断。文中出现的“心脏生物年龄年轻四岁”又是生物标志物分析,而非真实存活时间减少了四岁的直接证明。
资料来源|FDA司美格鲁肽心血管适应证(2024-03-08):https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or
资料来源|FDA替尔泊肽睡眠呼吸暂停适应证(2024-12-20):https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea
资料来源|FDA GLP-1药物安全标签更新(2026-11-09):https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
06|“衰老时钟”能测出生物年龄吗?它到底测的是什么?
chronological age(实际年龄)按出生日期计算,而 biological age(生物年龄)尝试用细胞、组织或器官的指标估计身体状态。所谓 ageing clocks(衰老时钟),常利用 DNA methylation(DNA甲基化:DNA上的化学修饰之一)、血液蛋白质或其他多维数据,通过统计模型预测年龄或相关健康风险。不同模型的训练目标可能完全不同:有的尽量预测实际年龄,有的预测疾病/死亡风险,有的监测随时间变化的生物过程。它们不是同一台“精确倒计时器”,更不是身份证上年龄的替代品。美国国家老龄研究所的资料也指出,目前已有多种基于不同分子指标的衰老时钟,研究人员仍在验证测量衰老速度和医学用途的准确性。
假设某药物让一项算法给出的心脏生物年龄估计值下降四岁,它首先证明的是“该算法分数发生了变化”;再进一步要证明这种变化可重复、与更少的心脏病或死亡事件有稳定联系,最后还要证明药物引起的分数变化确实导致了健康获益。2026年《Aging Cell》关于衰老时钟可信度的研究明确提出:时钟分数改善不必然转化为寿命或健康寿命延长,若把它当作替代临床终点,还需要长期研究验证。因此读本文涉及3年、4年的数字时,必须加上“某项指标估计值”的限定。
资料来源|美国国家老龄研究所2026财年资料:https://www.nia.nih.gov/about/budget/fiscal-year-2026-budget
资料来源|2026年衰老时钟评价研究:https://pmc.ncbi.nlm.nih.gov/articles/PMC13650178/
资料来源|个人层面限制综述:https://pubmed.ncbi.nlm.nih.gov/41403206/
07|表观遗传重编程:什么叫给细胞“重置开关”?
DNA(脱氧核糖核酸)像保存遗传信息的“文本”,而 epigenetics(表观遗传调控)更接近“对文本哪些段落可被读取、什么时候被读取的调节”。在衰老过程中,基因表达调控、蛋白质维持、细胞衰老、慢性炎症等多种过程会一起变化。2023年《Cell》更新的“12项衰老标志”是一套研究框架,其中 epigenetic alterations(表观遗传改变)只是重要部分之一。表观遗传重编程(epigenetic reprogramming)希望通过调节相关机制,让细胞恢复某些年轻状态的特征。这是具有吸引力的科学方向,但不能把“某些细胞标志恢复年轻”直接理解为“整个器官甚至人体被安全逆转年龄”。
难点在于,细胞需要维持自己的身份和功能:如果重编程过度,细胞可能失去原来的功能状态;对潜在不良增殖、长期安全性及不同组织的效果都需要验证。原文提到的NewLimit与其他生物科技公司,是在探索这一方向的实际可行性,而它们的融资、实验计划乃至早期动物数据都不是临床有效性的证明。真正重要的终点,是人体试验能否显示疾病指标与生活功能改善,且潜在风险处于可接受范围内。
资料来源|2023年衰老标志框架(Cell摘要):https://pubmed.ncbi.nlm.nih.gov/36599349/
资料来源|2026年衰老机制与临床转化综述:https://pmc.ncbi.nlm.nih.gov/articles/PMC13607713/
08|为什么长寿研发花钱多、失败也多?读懂药企合作、临床试验与资本热潮
原文写礼来与英矽智能的协议“worth up to $2.75bn”(最高可达27.5亿美元),诺华与BioAge Labs的协议“worth up to $550m”(最高可达5.5亿美元)。读财经报道时一定要注意 up to:这类金额通常表示潜在总对价上限,可能包括首付款、研发里程碑和未来商业化付款,而不是已到账现金。相似地,raised $18.4bn(融资184亿美元)表示资本投入,不等于长寿产品已有同等规模的销售收入,更不代表技术已得到监管认可。企业不一定自己完成所有研发,可通过许可、期权或合作协议分摊风险,等试验前景更明朗时再决定下一步投入。
药物开发需要从体外与动物研究进入多期人体试验,评估剂量、安全性、对照效果和长期结局,因此“进入后期试验”与“获批上市”之间仍存在实质距离。原文回顾Sirtris、Calico和Unity等项目,提醒我们历史上已有不少看似前景广阔却未兑现的抗衰老故事。对想通过新闻学习科学思辨的读者,可以坚持四个问题:证据来自细胞/动物还是人?受试者人数与健康状态如何?改善的是代理指标还是真正重要的临床结局?结果是经过独立同行评审,还是企业发布会上的初步数据?这些问题比“概念有多前沿”更能帮助判断报道分量。
资料来源|FDA抗衰老药物宣传说明:https://www.fda.gov/drugs/medication-health-fraud/medication-health-fraud-specific-diseases-and-conditions
资料来源|原文《经济学人》2026-11-03,企业融资、合作金额为原报道口径
10|阅读题目设计|雅思阅读风格
说明|采用IELTS Reading常见题型:单项选择、True/False/Not Given、句子填空、信息匹配与简答。英文题干附中文说明,参考答案统一集中在后面。
1|Multiple Choice(单项选择)
What is the main contrast in the article?
中文题意:文章最主要比较的是哪两种路线?
A. Two ways to calculate the price of a medicine.(两种药物定价方法)
B. Consumer longevity services and slower evidence-based drug development.(消费者长寿服务与更慢的循证药物研发)
C. Two brands of full-body MRI machines.(两种磁共振设备)
D. Two definitions of old age only.(仅仅两种年龄定义)
2|True / False / Not Given(判断)
The American College of Radiology says full-body screening has been proven to extend life in healthy people.
中文题意:美国放射学会认为,全身筛查已被证明能够延长健康人寿命。
3|Sentence Completion(句子填空)
The term “________” refers to tools that estimate biological age from molecular information.
中文题意:从文章中填入不超过两个单词:哪种工具利用分子信息估算生物年龄?
4|Matching Information(信息匹配)
Match each activity to the relevant approach: A. consumer longevity services; B. biotech/pharmaceutical development. (i) Full-body MRI subscriptions; (ii) Clinical testing of a drug for pulmonary fibrosis.
中文题意:把两项活动归类:A消费者长寿服务;B生物医药研发。(i)全身MRI年度订阅;(ii)肺纤维化候选药物的人体试验。
5|Short Answer(简答)
What does “worth up to $2.75bn” tell us about Lilly’s deal with Insilico?
中文题意:“worth up to $2.75bn”在原文中如何限定礼来与英矽智能的协议金额?
参考答案与解析
1|B
解析:原文第4段明确划分两类产业:一类面向消费者销售扫描、补充剂与诊所体验,另一类由生物科技公司和药企合作研发潜在抗衰老药物。其他选项均不是全篇结构。
2|False
解析:文章明确写到美国放射学会认为,尚无记录在案的证据证明面向普通人的全身筛查具有成本效益或能够延长寿命。题干将“无证据”反转成“已证明”,因此错误。
3|ageing clocks
解析:原文 The yardstick was “ageing clocks”, which estimate how old a body really is...;关键是 estimate(估算),不是直接测出实际可多活多少年。
4|(i) A;(ii) B
解析:年度MRI订阅属于消费者检测服务;针对特发性肺纤维化的候选药进入临床试验属于药物研发路线。文章区分的不是“是否使用高科技”,而是证据与监管路径。
5|The deal has a potential value of up to $2.75bn, not necessarily an amount already paid.
解析:up to 表示“上限”;协议价值可能包含后续里程碑付款,不能仅凭新闻断言全部金额已到账。
11|每日美句
While the results are gathered, consumers will keep seeking immortality elsewhere.
翻译:在等待研究结果出炉的同时,消费者仍将继续到其他地方寻找“永生”的希望。
句式迁移|While + 主语 + 被动语态,主句 + will keep + doing:强调“正式证据还在积累,而某种社会行为持续发生”。例如:While the evidence is reviewed, people will keep asking difficult questions.(在证据被审查期间,人们仍会不断提出难题。)
12|本文总结
长寿已经形成了庞大的商业市场,但“某项技术很先进”“某个生物标志物改善”“真正延长人的健康寿命”,是三种完全不同的结论。读完本文,最值得保留的判断方法是:先看研究对象,再看对照与证据,最后看是否改善真实的健康结局。对科学保持好奇,也要对营销保持辨别能力。
结尾互动|如果一家长寿诊所向你推销全身MRI扫描、NAD+疗程和“年轻四岁”的生物年龄报告,你最想先问它哪一个问题?欢迎在评论区分享你的判断。
编辑|润泽
排版|润泽
参考来源|网友整理全文,“每日英语听力”《外刊精读》选段;《经济学人》2026年11月3日报道;上述机构与学术公开资料。关注「润泽学习中」,私信回复关键词“11.10 外刊精读”,即可了解原文PDF学习资料获取方式(以实际提供情况为准)。
关注「润泽学习中」公众号|让学习更有方法